SPR-based binding assays for functional analysis of multivalent molecules
By immobilizing bispecific antigens on the SPR chip, allowing bispecific antibodies to bind two antigens at the same time, solving the problem of difficult to measure the interaction between multispecific antibodies and different antigens in the prior art, and achieving binding to bispecific antibodies Accurate measurement of strength and evaluation of antibody activity.
Patent Information
- Application Number
- CN202080025733.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-03-29
- Filing Date
- 2020-03-25
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2040-03-25
AI Technical Summary
The prior art is difficult to effectively measure the simultaneous interaction of multispecific antibodies with their different antigens, especially in determining the affinity-based binding strength of bispecific antibodies.
By immobilizing bispecific antigens as heterodimer molecules on a surface plasmon resonance (SPR) chip, bispecific antibodies allow binding at the same time to both antigens, independently of affinity, to determine the kinetics and affinity effects of affinity binding.
Accurate measurement of affinity-driven binding strength for bispecific antibodies is achieved, reducing off-target binding and side effects, improving target specificity, and able to evaluate the relative activity and purity of the antibodies.
Smart Images

Figure CN113646622B_ABST
Abstract
Description
[0001] The present invention belongs to the field of functional assays. Herein, a novel SPR-based binding assay is reported for measuring the simultaneous interaction of a multispecific antibody with its different antigens. The method is particularly suitable for determining and measuring the affinity-based binding strength of bispecific antibodies. Background Art
[0002] SPR (surface plasmon resonance) is a biosensor-based technology to measure real-time protein-protein interactions. SPR technology has become a standard tool in the field of biopharmaceutical research and development (see, e.g., MACooper, Nat. Rev. Drug Dis. 1 (2002) 515-528; D. G. M. Myszka, J. Mol. Recognit. 12 (1999) 390-408; R. L. Rich and D. G. M. Myszka, J. Mol. Recognit. 13 (2000) 388-407; D. G. M. Myszka and R. L. Rich, Pharm. Sci. Technol. Today 3 (2000) 310-317; R. Karlsson and A. Faelt, J. Immunol. Meth. 200 (1997) 121-133), and is often used to determine the rate constants of macromolecular interactions. The ability to determine the association and dissociation kinetics of molecular interactions provides detailed insights into the mechanisms of complex formation (see, e.g., TAMorton, DGMyszka, Meth. Enzymol. 295 (1998) 268-294). This information is becoming an important part of the selection and optimization process of monoclonal antibodies and other biopharmaceutical products (see, e.g., K. Nagata and H. Handa, in Real-time analysis of biomolecular interactions, Springer, 2000; RLRich and DGMyszka, Curr. Opin. Biotechnol. 11 (2000) 54-61; ACMalmborg and CA Borrebaeck, J. Immunol. Meth. 183 (1995) 7-13; W. Huber and F. Mueller, Curr. Pharm. Des. 12 (2006) 3999-4021). In addition, SPR technology allows determination of, for example, the binding activity (binding capacity) of an antibody binding target.
[0003] Only a few technologies allow functional assessment of two or more interactions in one method (e.g., suspension array technology, reviewed in Y. Leng, Chem. Soc. Rev 44 (2015); time-resolved fluorescence assays (see, e.g., TC. Liu, Clin. Biochem. 47 (2014) 439-444)). These technologies utilize the parallel detection of different fluorophores. Furthermore, there are optical biosensors which allow online measurement of multiple interactions and thus sequential measurements (see, for example, D. G. Myszka, J. Mol. Recognit. 12 (1999) 390-408; R. L. Rich and D. G. M. Myszka, J. Mol. Recognit. 13 (2000) 388-407; D. G. M. Myszka and R. L. Rich, Pharm. Sci. Technol. Today 3 (2000) 310-317; R. Karlsson and A. Faelt, J. Immunol. Meth. 200 (1997) 121-133).
[0004] WO 2009 / 058564 discloses a kinetic assay for measuring the binding kinetics of a dimeric ligand (e.g., hCD80-mIg fusion protein or hCD86-mIg fusion protein) coated on a sensor chip and a dimeric analyte (e.g., the mutant CTLA-4-Ig fusion protein of this invention) in a mobile phase.
[0005] WO 2009 / 062942 discloses a semi-universal dual affinity polypeptide having different binding affinities for target and capture ligand, respectively, for use in chromatography. This invention can use binding domains that are specific and strong but cannot be destroyed under normal elution conditions.
[0006] WO 2010 / 112193 discloses an SPR-based assay for determining bispecific antibodies <igf-1r-egfr>Simultaneous binding to EGFR and IGF1R with bispecific antibodies immobilized on the chip.
[0007] WO 2011 / 143545 discloses an SPR-based assay for determining simultaneous binding of a bispecific antibody to two different antigens, wherein the bispecific antibody is bridged between an immobilized antigen-Fc-fusion and a soluble antigen-Fc-fusion.
[0008] WO 2015 / 104406 discloses detecting the binding affinity of multispecific polypeptides to corresponding targets, human Her2 and human CTLA-4, by surface plasmon resonance, wherein biotinylated multispecific polypeptides are captured on a sensor chip.
[0009] Meschendoerfer, W. et al. disclosed an SPR-based assay that enables full functional analysis of bispecific molecules (J. Pharm. Biomed. Anal. 132 (2016) 141-147).
[0010] WO 2016 / 082044 discloses biparatopic anti-HER2 antibodies, wherein the first antigen binding moiety and the second antigen binding moiety bind to different epitopes on the same antigen. To determine the binding of the individual paratopes of the biparatopic anti-HER2 antibodies to monomeric and dimeric HER2, the HER2 ECD and HER2-Fc fusions are immobilized on a sensor chip and contacted with the corresponding monovalent monospecific or bivalent monospecific antibodies. In contrast, to determine the cis and trans binding properties of the biparatopic bivalent antibodies, the antibodies are immobilized on the sensor chip via anti-human Fc antibodies.
[0011] WO 2016 / 059068 discloses VEGFR-2 binding polypeptides, in particular, the dimeric mature Z variants are produced and characterized using SPR analysis. It is also shown that the dimeric Z variants are able to bind to VEGFR-2 expressed on the surface of mammalian cells.
[0012] WO 2017 / 027422 discloses a construct having a SIRP-α domain or a variant thereof. The SIRP-α polypeptide or construct includes a SIRP-αD1 variant fused to an Fc domain monomer, human serum albumin (HSA), an albumin binding peptide, or a polyethylene glycol (PEG) polymer.
[0013] US 2014 / 0193408 discloses soluble proteins for use as therapeutic agents. It particularly discloses a soluble, multispecific, multivalent binding protein as a subject, the binding protein comprising a complex of two heterodimers, wherein each heterodimer is essentially composed of the following: (i) a first single-chain polypeptide comprising: (a) an antibody heavy chain sequence having VH, CH1, CH2 and CH3 regions; and (b) a monovalent region of a mammalian binding molecule fused to the VH region; and (ii) a second single-chain polypeptide comprising: (c) an antibody light chain sequence having VL and CL regions; and (d) a monovalent region of a mammalian binding molecule fused to the VL region; characterized in that each pair of VH and VL CDR sequences is specific for an antigen, so that the total price of the soluble protein is six.
[0014] US 2018 / 0009892 discloses anti-ROR1 antibodies.
[0015] WO 2016 / 004383 discloses tumor-selective CTLA-4 antagonists. Summary of the invention
[0016] Here we report a novel binding assay for measuring the simultaneous interaction of multivalent antibodies with their different antigens. This method is particularly suitable for determining and measuring the avidity-based binding strength of bispecific antibodies, including those that bind to two different epitopes on the same antigen.
[0017] A novel binding assay is reported herein for measuring the avidity-based binding strength (i.e., the gain in binding affinity based on affinity binding) of at least bivalent bispecific antibodies that simultaneously bind to corresponding one or more antigens with their two binding sites. In one embodiment, the binding assay is an ELISA or SPR-based binding assay.
[0018] A novel binding assay is reported herein for measuring the avidity-based binding strength (i.e., gain in binding affinity based on affinity binding) of at least two-valent bispecific antibodies simultaneously binding to their targets / antigens. In one embodiment, the binding assay is an ELISA or SPR-based binding assay.
[0019] The present invention is based at least in part on the discovery that avidity-based binding strength can be determined separately from affinity-based binding effects by using a method in which the two antigens are immobilized as heterodimeric molecules (on a chip surface in the case of an SPR-based method or on a solid phase in the case of an ELISA), e.g. using immobilized bispecific antigens, e.g. as bispecific Fc fusions. In a preferred embodiment, the method is a surface plasmon resonance-based method and the two antigens are immobilized on a chip surface.
[0020] In the arrangement according to the invention, in which the linked different antigens are defined immobilized, i.e. in an arrangement in which the individual antigens are evenly distributed, the bivalent bispecific antibody will bind both antigens simultaneously, since the two antigens are suitably spaced. This defined simultaneous binding allows the determination of affinity binding independently of affinity binding. Furthermore, the dimer / bispecific antigens show homogeneous and avid interactions at any level of immobilization.
[0021] Immobilizing the fused (different) antigens connected via a linker on a biosensor chip creates an environment in which individual copies of both antigens are in close proximity to each other, independent of the surface density of the fused heterodimeric antigens according to the invention. This opens the way to new applications, e.g.
[0022] 1) Kinetic evaluation of affinity interactions: The fused heterodimeric antigens according to the invention allow co-localization of the two targets of the bispecific antibody even at very low surface densities of the fused heterodimeric antigens. This low surface density with defined proximity of different antigens (due to the close proximity of the second copy of one of the antigens) is required in order to determine kinetic binding parameters without limiting mass transfer or interfering with rebinding.
[0023] 2) Quality assessment of samples relative to reference standards: In this setup, antibodies capable of affinity binding will always bind to both specificities, since after the initial first binding event, the local concentration of the second binding partner is greatly increased due to the close proximity. Avidity effects have a dramatic impact on the dissociation rate constant, kd, of the antibody from its antigen, so relative activity can be assessed in relation to the potency of the antibody, simply by reading out a single response during the dissociation phase of the SPR measurement. Since kd affects the equilibrium concentration, this approach can also be used to assess the bispecific binding capacity of an antibody to all of its targets by ELISA or similar methods.
[0024] The difference between 1) and 2) is as follows:
[0025] - In case 2, the sample does not need to be titrated / not titrated;
[0026] - In case of 2, only a single sample concentration is needed to assess relative activity;
[0027] - Sample evaluation does not rely on performing kinetic fits.
[0028] One aspect of the invention is a method for determining the avidity-based binding strength of at least a bispecific binder comprising a first binding site that specifically binds to a first antigen and a second binding site that specifically binds to a second antigen, the method comprising the steps of:
[0029] - determining the affinity-based binding strength of the bispecific binder from changes in a surface plasmon resonance signal obtained by applying a solution comprising the bispecific binder to a solid phase conjugated to a first antigen-second antigen fusion polypeptide.
[0030] One aspect of the invention is a method for determining the avidity-based binding strength of at least a bispecific binder to a first antigen and a second antigen, the binder comprising a first binding site that specifically binds to the first antigen and a second binding site that specifically binds to the second antigen, the method comprising the steps of:
[0031] a) capturing the first antigen-second antigen fusion polypeptide on a solid phase and determining / measuring / confirming a first surface plasmon resonance response,
[0032] b) applying a solution comprising the bispecific binder to the solid phase of step a) to form a captured first antigen-second antigen fusion polypeptide-bispecific binder complex and determining / measuring / confirming a second surface plasmon resonance response,
[0033] c) determining / calculating the affinity-based binding strength of the bispecific binder for the first and second antigens from the difference between the first and second surface plasmon resonance responses.
[0034] One aspect of the invention is a method for determining the avidity-based binding strength of at least a bispecific binder to a first antigen and a second antigen, the binder comprising a first binding site that specifically binds to the first antigen and a second binding site that specifically binds to the second antigen, the method comprising the steps of:
[0035] a) capturing the first antigen-second antigen fusion polypeptide on a solid phase (and determining / measuring / confirming the baseline surface plasmon resonance response),
[0036] b) applying a first solution comprising a first concentration of the bispecific binder to the solid phase of step a) to form a captured first antigen-second antigen fusion polypeptide-bispecific binder complex and determining / measuring / confirming a first surface plasmon resonance response, (whereby the first surface plasmon resonance response is a change in the surface plasmon resonance response obtained by applying the bispecific binder to the solid phase relative to a baseline surface plasmon resonance response),
[0037] c) dissociating the captured first antigen-second antigen fusion polypeptide-bispecific binder complex and thereby regenerating the solid phase,
[0038] d) repeating at least steps b) and c) with a second solution comprising a second concentration of the bispecific binder and determining / measuring / confirming a second surface plasmon resonance response, wherein all concentrations are different,
[0039] e) determining / calculating the affinity-based binding strength of the bispecific binder for the first and second antigens from the surface plasmon resonance response as determined in the previous step.
[0040] In one embodiment of all aspects and embodiments of the invention at least the bispecific binding partner is a bispecific antibody.
[0041] In one embodiment of all aspects and embodiments of the invention, at least the bispecific antibody is a bispecific, bivalent antibody.
[0042] In one embodiment of all aspects and embodiments of the invention, at least the bispecific antibody is a bispecific, trivalent antibody.
[0043] In one embodiment of all aspects and embodiments of the invention, at least the bispecific antibody is a bispecific, tetravalent antibody.
[0044] In one embodiment of all aspects and embodiments of the invention, the first antigen is at least a fragment of an epitope of said first antigen comprising the first binding site of the bispecific binder, and the second antigen is at least a fragment of an epitope of said second antigen comprising the second binding site of the bispecific binder.
[0045] In one embodiment of all aspects and embodiments of the invention, the first antigen and the second antigen are different.
[0046] In one embodiment of all aspects and embodiments of the invention, the first and second antigens are non-antibody antigens. The term "non-antibody antigen" refers to a polypeptide that is not derived from an antibody, i.e., a non-antibody protein, i.e., does not contain any part of an antibody or its fragment.
[0047] In one embodiment of all aspects and embodiments of the invention the solid phase is a surface plasmon resonance chip.
[0048] In one embodiment of all aspects and embodiments of the invention, the second concentration differs from the first concentration by at least 2-fold, 3-fold, 4-fold, 5-fold or 10-fold.
[0049] One aspect of the invention is a fusion polypeptide of a first antigen and a second antigen of a bispecific binder.
[0050] This fusion protein according to the present invention is referred to herein as a "first antigen-second antigen fusion polypeptide".
[0051] In one embodiment of all aspects and embodiments of the invention, the fusion polypeptide according to the invention comprises as first antigen at least a fragment of a first antigen (comprising an epitope of at least the first binding site of the bispecific binder) and as second antigen at least a fragment of a second antigen (comprising an epitope of at least the second binding site of the bispecific binder).
[0052] In one embodiment of all aspects and embodiments of the invention, the fusion polypeptide according to the invention is a linear polypeptide wherein the first antigen is at the C-terminus and the second antigen is at the N-terminus, or vice versa. In one embodiment, the first antigen and the second antigen are linked by a peptide linker. In one embodiment, the peptide linker comprises a tag for fixation to a solid phase.
[0053] In one embodiment of all aspects and embodiments of the present invention, the fusion polypeptide is a heterodimeric polypeptide comprising a first polypeptide and a second polypeptide, the first polypeptide being a fusion polypeptide of a first antigen and a first antibody heavy chain Fc region polypeptide comprising a first set of heterodimerization mutations, the second polypeptide being a fusion polypeptide of a second antigen and a second antibody heavy chain Fc region polypeptide comprising a second set of heterodimerization mutations, the second set of heterodimerization mutations being complementary to the first set of heterodimerization mutations. In one embodiment, the first antigen and the second antigen are at the N-terminus of the corresponding first or second Fc region polypeptide. In one embodiment, one or both of the Fc region polypeptides comprise a tag for fixation to a solid phase. In one embodiment, the tag is located at the C-terminus of the corresponding Fc region polypeptide. In one embodiment, the Fc region is of human IgG1 isotype. In one embodiment, the first and second sets of heterodimerization mutations are T366W and T366S / L368A / Y407V, respectively, and vice versa. In one embodiment, the tag for fixation is a histidine tag or biotin.
[0054] In one embodiment of all aspects and embodiments of the present invention, the fusion polypeptide is a heterodimeric polypeptide comprising a first polypeptide and a second polypeptide, the first polypeptide being a fusion polypeptide of a first antigen and a first antibody heavy chain constant region polypeptide comprising a first set of heterodimerization mutations, the second polypeptide being a fusion polypeptide of a second antigen and a second antibody heavy chain constant region polypeptide comprising a second set of heterodimerization mutations, the second set of heterodimerization mutations being complementary to the first set of heterodimerization mutations. In one embodiment, the first antigen and the second antigen are located at the N-terminus of the corresponding first or second constant region polypeptide. In one embodiment, one or both of the constant region polypeptides comprises a tag for fixation to a solid phase. In one embodiment, the tag is located at the C-terminus of the corresponding Fc region polypeptide. In one embodiment, the Fc region belongs to the human IgG1 isotype. In one embodiment, the first and second sets of heterodimerization mutations are T366W and T366S / L368A / Y407V, respectively, and vice versa. In one embodiment, the tag for fixation is a histidine tag or biotin.
[0055] Thus, in general, one aspect of the invention is a heterodimeric fusion polypeptide comprising
[0056] i) a first proteinaceous portion, and
[0057] ii) a second proteinaceous portion,
[0058] in
[0059] - the first proteinaceous part and the second proteinaceous part are
[0060] i) at least a first and a second antigen of a bispecific antibody, the at least bispecific antibody comprising a first binding site that specifically binds to a first proteinaceous moiety and a second binding site that specifically binds to a second proteinaceous moiety, or
[0061] ii) two copies of the same antigen in a bivalent monospecific antibody,
[0062] - the first proteinaceous part is fused to the N-terminus of the Fc region polypeptide of the first antibody heavy chain of the IgG1 subtype,
[0063] - a second proteinaceous part is fused to the N-terminus of a second antibody heavy chain Fc region polypeptide of the IgG1 subtype,
[0064] - the first heavy chain Fc region polypeptide and the second heavy chain Fc region polypeptide form a disulfide-bonded heterodimer,
[0065] - one or both of the heavy chain Fc region polypeptides comprises a tag at its C-terminus for fixation to a solid phase, and
[0066] - the first Fc-region polypeptide and the second Fc-region polypeptide comprise the mutations T366W and T366S / L368A / Y407V, respectively.
[0067] In one embodiment of all aspects and embodiments of the invention the proteinaceous moiety is a polypeptide.
[0068] Such heterodimeric fusion polypeptides are fusion polypeptides of at least the first antigen and the second antigen of the bispecific binder / antibody.
[0069] Likewise, this heterodimeric fusion polypeptide is a fusion polypeptide of two copies of the antigen of the bivalent monospecific binder / antibody.
[0070] In one embodiment of all aspects and embodiments of the invention, the fusion polypeptide according to the invention comprises only one (ie exactly one) first antigen and only one (ie exactly one) second antigen.
[0071] In one embodiment of all aspects and embodiments of the invention, the first antigen and the second antigen are not the same polypeptide.
[0072] In one embodiment of all aspects and embodiments of the invention the first proteinaceous moiety and the second proteinaceous moiety are not from the same polypeptide.
[0073] One aspect of the present invention is the use of a fusion polypeptide of a first antigen and a second antigen of at least a bispecific binder according to the present invention in a surface plasmon resonance method to determine the affinity-based binding strength of the at least bispecific binder to the first and second antigens, the binder comprising a first binding site that specifically binds to the first antigen and a second binding site that specifically binds to the second antigen.
[0074] One aspect of the present invention is the use of a fusion polypeptide of a first antigen and a second antigen of at least a bispecific binder according to the present invention in an ELISA method to determine the affinity-based binding strength of the at least bispecific binder to the first and second antigens, the binder comprising a first binding site that specifically binds to the first antigen and a second binding site that specifically binds to the second antigen.
[0075] One aspect of the invention is an affinity chromatography column comprising a fusion polypeptide of at least the first antigen and the second antigen of the bispecific binder according to the invention, the fusion polypeptide serving as chromatographic ligand.
[0076] One aspect of the invention is a method for separating / purifying an at least bispecific binder having avidity-based binding to a first and a second antigen, comprising a first binding site that specifically binds to the first antigen and a second binding site that specifically binds to the second antigen, from an at least bispecific binder that does not have avidity-based binding to the same first and second antigens, the method comprising the steps of:
[0077] a) applying a solution comprising at least a bispecific binder with and without affinity-based binding to a first and a second antigen to an affinity chromatography column according to the invention,
[0078] b) recovering the at least bispecific binder having affinity-based binding to the first and second antigens from the column, thereby separating / purifying the at least bispecific binder from binders not having affinity-based binding to the same first and second antigens.
[0079] One aspect of the invention is a method for purifying (from product-related and / or process-related impurities) an at least bispecific binder having affinity-based binding to a first antigen and a second antigen, the at least bispecific binder comprising a first binding site that specifically binds to the first antigen and a second binding site that specifically binds to the second antigen, the method comprising the steps of:
[0080] a) applying a solution comprising the at least bispecific binder having affinity-based binding to a first antigen and a second antigen (and process-related and / or product-related impurities) to an affinity chromatography column according to the invention,
[0081] b) optionally washing the column, wherein the at least bispecific binder having avidity-based binding to the first antigen and the second antigen remains bound to the column, and
[0082] c) recovering the at least bispecific binder having affinity-based binding to the first antigen and the second antigen from the column and thereby purifying the at least bispecific binder (from product-related and / or process-related impurities).
[0083] One aspect of the invention is a surface plasmon resonance chip immobilized in at least one flow cell comprising a fusion polypeptide of at least a first antigen and a second antigen of a bispecific binder according to the invention.
[0084] According to one aspect of the present invention is a method for producing a surface plasmon resonance chip comprising a fusion polypeptide of at least a first antigen and a second antigen of a bispecific binder according to the present invention immobilized in at least one flow cell, the method comprising the following steps:
[0085] - Immobilizing a fusion polypeptide of at least the first antigen and the second antigen of the bispecific binder according to the invention directly or via a specific binding pair in at least one flow cell of a surface plasmon resonance chip.
[0086] According to one aspect of the invention is a method for assessing the quality of a sample comprising at least a bivalent bispecific antibody, the method comprising the following steps:
[0087] - applying solutions containing covalent fusion polypeptides at different concentrations to the SPR chip on which the bivalent bispecific antibody has been immobilized, and then monitoring the SPR signal, or vice versa, wherein the covalent fusion polypeptides contain the first antigen of the bivalent bispecific antibody at one end and the second antigen of the bivalent bispecific antibody at a different second end, respectively.
[0088] as well as
[0089] - comparing the determined reading to a reference sample and thereby determining the quality of said sample comprising said at least bivalent bispecific antibody,
[0090] wherein the at least bivalent bispecific antibody comprises a first binding site that specifically binds to a first non-antibody antigen and a second binding site that specifically binds to a different second non-antibody antigen.
[0091] In one embodiment, the method comprises the following steps:
[0092] - applying solutions containing covalent fusion polypeptides at different concentrations to the SPR chip on which the bivalent bispecific antibody has been immobilized, and then monitoring the SPR signal, or vice versa, wherein the covalent fusion polypeptides contain the first antigen of the bivalent bispecific antibody at one end and the second antigen of the bivalent bispecific antibody at a different second end, respectively.
[0093] - Plot the binding response (in resonance units) against the corresponding sample concentration,
[0094] - fit the data points of the obtained plot using a 2-parameter line fit and determine the y-intercept as the readout,
[0095] - comparing the determined readings with the readings of reference samples analyzed and processed in the same way by means of a parallel line transformation,
[0096] thereby determining the quality / purity / homogeneity of a sample comprising the at least bivalent bispecific antibody,
[0097] wherein the at least bivalent bispecific antibody comprises a first binding site that specifically binds to a first non-antibody antigen and a second binding site that specifically binds to a different second non-antibody antigen.
[0098] According to one aspect of the present invention is a method for selecting a cell line producing / expressing / secreting an at least bivalent bispecific antibody, the method comprising the following steps:
[0099] - providing a corresponding supernatant of an isolated culture of a cell line from a plurality of recombinant mammalian cell lines producing / expressing / secreting the (heterologous) at least bivalent bispecific antibody,
[0100] - for each cell line, applying a solution containing a covalent fusion polypeptide at different concentrations to the SPR chip, and then monitoring the SPR signal, or vice versa, wherein the covalent fusion polypeptide comprises the first antigen of the bivalent bispecific antibody at one end and the second antigen of the bivalent bispecific antibody at a different second end, and the bivalent bispecific antibody from the culture supernatant of the cell line has been immobilized on the SPR chip
[0101] - comparing the determined readouts to each other and thereby determining the relative quality of said at least bivalent bispecific antibody produced by each cell line,
[0102] as well as
[0103] - selecting at least one cell line based on the relative quality of said at least bivalent bispecific antibody produced,
[0104] wherein the at least bivalent bispecific antibody comprises a first binding site that specifically binds to a first non-antibody antigen and a second binding site that specifically binds to a different second non-antibody antigen.
[0105] In one embodiment, the method comprises the following steps:
[0106] - providing a corresponding supernatant of an isolated culture of a cell line from a plurality of recombinant mammalian cell lines producing / expressing / secreting the (heterologous) at least bivalent bispecific antibody,
[0107] - for each cell line, applying a solution comprising a covalent fusion polypeptide comprising the first antigen of the bivalent bispecific antibody at one end and the second antigen of the bivalent bispecific antibody at a different second end to the SPR chip at different concentrations, and then monitoring the SPR signal, or vice versa, the bivalent bispecific antibody from the culture supernatant of the cell line having been immobilized on the SPR chip,
[0108] - Plot the binding response (in resonance units) against the corresponding sample concentration,
[0109] - fitting the data points of the obtained graph using a 2-parameter line fit and determining the y-intercept as readout, thereby determining the relative quality of said at least bivalent bispecific antibody produced by each cell line,
[0110] as well as
[0111] - selecting at least one cell line based on the relative quality of said at least bivalent bispecific antibody produced,
[0112] wherein the at least bivalent bispecific antibody comprises a first binding site that specifically binds to a first non-antibody antigen and a second binding site that specifically binds to a different second non-antibody antigen.
[0113] Prior to using SPR, all the methods outlined can also be used in an ELISA format, where the readout is the assay signal (color intensity) rather than the SPR signal. DETAILED DESCRIPTION
[0114] Herein is reported a novel SPR-based binding assay for measuring the avidity-based binding strength, i.e. the gain in binding affinity based on affinity binding, of an at least bivalent or at least bispecific antibody that binds simultaneously or to its two targets / antigens, respectively, with its two binding sites.
[0115] The present invention is based at least in part on the discovery that avidity-based binding strength can be determined separately from affinity-based binding effects by using a surface plasmon resonance-based method, wherein the antigen of a bivalent monospecific antibody is immobilized on a chip surface as a dimer, i.e., using an immobilized bivalent dimeric antigen, e.g., as a dimeric Fc fusion.
[0116] The present invention is based at least in part on the discovery that by using a surface plasmon resonance-based method, avidity-based binding strength can be determined separately from affinity-based binding effects, wherein at least the two antigens of a bispecific antibody are immobilized on a chip surface as bispecific molecules, i.e., using immobilized bispecific antigens, e.g., as bispecific Fc fusions.
[0117] The present invention is based, at least in part, on the discovery that by presenting antigens in covalently linked form of bivalent monospecific antibodies on the surface of an SPR chip, the affinity obtained by simultaneous binding to two binding sites can be determined.
[0118] The present invention is based, at least in part, on the discovery that by presenting at least two antigens of a bispecific binder in covalently linked form on the surface of an SPR chip, the affinity obtained by simultaneous bispecific binding can be determined.
[0119] The present invention is further based at least in part on the discovery that, using the SPR assay according to the present invention, affinity-driven binding improvements of bivalent monospecific or at least bispecific binders can be determined. This concept allows, for example, the selection of bispecific binders with increased target specificity and thereby reduces off-target binding and side effects.
[0120] definition
[0121] General information about the nucleotide sequences of human immunoglobulin light and heavy chains is given in: Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th Edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991). The amino acid positions of all constant regions and domains of heavy and light chains can be numbered according to the Kabat numbering system described in Kabat, et al., Sequences of Proteins of Immunological Interest, 5th Edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991), and are referred to herein as "numbered according to Kabat". Specifically, the Kabat numbering system (see pp. 647-660 of Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991)) is used for the light chain constant domains CL of the kappa and lambda isotypes, and the EU index numbering system of Kabat (see pp. 661-723) is used for the constant heavy chain domains (CH1, hinge, CH2, and CH3, which are further classified herein by being referred to in this context as "numbering according to the EU index of Kabat").
[0122] The term "about" means a range of + / -20% of the value that follows. In one embodiment, the term "about" means a range of + / -10% of the value that follows. In one embodiment, the term "about" means a range of + / -5% of the value that follows.
[0123] "Affinity" or "binding affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can often be expressed in terms of the dissociation constant (K D ) indicates that the dissociation constant is the sum of the dissociation rate constant and the association rate constant (k off and k on ). Thus, equivalent affinities can include different rate constants as long as the ratio of the rate constants remains the same. Affinity can be measured by conventional methods known in the art, including those described herein. A particular method for measuring affinity is surface plasmon resonance (SPR).
[0124] The term "antibody" herein is used in the broadest sense and includes various antibody structures, including but not limited to monoclonal antibodies, multispecific antibodies (eg, bispecific antibodies, trispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity.
[0125] Antibodies generally comprise two so-called light chain polypeptides (light chains) and two so-called heavy chain polypeptides (heavy chains). Each of the heavy chain polypeptides and the light chain polypeptides contains a variable domain (variable region) (usually the amino terminal portion of the polypeptide chain), which comprises a binding region capable of interacting with an antigen. Each of the heavy chain polypeptides and the light chain polypeptides comprises a constant region (usually the carboxyl terminal portion). The constant region of the heavy chain mediates the binding of antibodies i) to cells (such as phagocytes) carrying Fcγ receptors (FcγR) or ii) to cells carrying neonatal Fc receptors (FcRn) (also referred to as Brambell receptors). It also mediates the binding to some factors, including factors of the classical complement system, such as components (C1q). The constant domain of the heavy chain of an antibody comprises a CH1 domain, a CH2 domain, and a CH3 domain, while the light chain comprises only one constant domain CL, which can be a κ isotype or a λ isotype.
[0126] The variable domain of an immunoglobulin light or heavy chain comprises different segments, namely four framework regions (FR) and three hypervariable regions (HVR).
[0127] The "class" of an antibody refers to the type of constant domain or constant region possessed by the heavy chain of the antibody. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and some of them can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.
[0128] The term "binding (to an antigen)" refers to the binding of an antibody to its antigen in an in vitro assay, in one embodiment of a binding assay, wherein the antibody is bound to a surface and the binding of the antigen to the antibody is measured by surface plasmon resonance (SPR). Binding refers to, for example, the measurement of the binding ability of an antibody to target A or target B or to a capture molecule (e.g., anti-human Fab capture of an antibody).
[0129] The term "monoclonal antibody" as used herein refers to an antibody obtained from a substantially homogeneous antibody population, that is, except for possible variant antibodies (e.g., containing naturally occurring mutations or produced during the production of monoclonal antibody preparations, such variants are usually presented in small amounts), each antibody comprising the population is identical and / or binds to the same epitope. Contrary to the polyclonal antibody preparations that typically include different antibodies for different determinants (epitopes), each monoclonal antibody in the monoclonal antibody preparation is directed to a single determinant on the antigen. Therefore, the modifier "monoclonal" represents that the feature of an antibody is obtained from a substantially homogeneous antibody population, and should not be interpreted as requiring antibody to be produced by any ad hoc method. For example, the monoclonal antibody used according to the present invention can be prepared by a variety of techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of human immunoglobulin loci, such methods and other exemplary methods for preparing monoclonal antibodies are described herein.
[0130] As used herein, the term "hypervariable region" or "HVR" refers to the regions of an antibody variable domain that are hypervariable in sequence ("complementarity determining regions" or "CDRs") and / or form structurally defined loops ("hypervariable loops") and / or contain antigen contact residues ("antigen contact points"). Typically, an antibody comprises six HVRs: three in VH (H1, H2, H3) and three in VL (L1, L2, L3). Exemplary HVRs herein include:
[0131] (a) hypervariable loops present at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987));
[0132] (b) CDRs present at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991));
[0133] (c) antigenic contact points present at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al., J. Mol. Biol. 262:732-745 (1996)); and
[0134] (d) a combination of (a), (b) and / or (c), comprising HVR amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3) and 94-102 (H3).
[0135] Unless otherwise indicated, HVR residues and other residues in the variable domain (eg, FR residues) are numbered herein according to Kabat et al.
[0136] The term "valent" as used in this application indicates the presence of a specified number of binding sites in a (antibody) molecule. Thus, the terms "bivalent", "tetravalent" and "hexavalent" indicate the presence of two binding sites, four binding sites and six binding sites in a (antibody) molecule, respectively. A bispecific antibody as reported herein is a preferred embodiment of "bivalent".
[0137] The term "binding affinity" refers to the strength of the interaction of a single binding site with its corresponding target. Affinity can be determined experimentally, for example, by measuring the association (kA) and dissociation (kD) kinetic constants of antibody and antigen at equilibrium (see Figure 2 ).
[0138] The term "binding affinity" indicates the combined strength of the interaction of multiple binding sites of a molecule (antibody) with the same target. Avidity is therefore the combined synergistic strength of the bond affinities, not the sum of the bonds. Necessary conditions for affinity are: multivalency of the molecule (e.g., antibody) or functional multimer for one target (antigen), - multiple accessible epitopes on one soluble target or multiple binding of the antibody to one epitope each located on multiple immobilized targets.
[0139] There is no difference in complex association between affinity binding and avidity binding. However, dissociation of complexes with affinity binding depends on the simultaneous dissociation of all binding sites involved. Therefore, the increase in binding strength due to affinity binding (compared to affinity binding) depends on the dissociation kinetics / complex stability: the greater (higher) the complex stability, the less likely all relevant binding sites will dissociate simultaneously; for very stable complexes, the difference between affinity binding and avidity binding is essentially zero; - the less (lower) the complex stability, the greater the probability that all relevant binding sites will dissociate simultaneously; the difference between affinity binding and avidity binding increases.
[0140] Multispecific Antibodies
[0141] In certain embodiments, the antibody is a multispecific antibody, such as a bispecific antibody. A multispecific antibody is a monoclonal antibody that has binding specificity for at least two different sites. In certain embodiments, one of the binding specificities is for a first antigen, and the other is for a different second antigen. In certain embodiments, a multispecific antibody can bind to two different epitopes of the same antigen. Multispecific antibodies can also be used to localize cytotoxic agents to cells expressing antigens. Multispecific antibodies can be prepared as full-length antibodies or antibody fragments.
[0142] Techniques for preparing multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs with different specificities (see Milstein, C. and Cuello, AC, Nature 305 (1983) 537-540, WO 93 / 08829, and Traunecker, A. et al., EMBO J. 10 (1991) 3655-3659) and "knob-in-hole" engineering (see, e.g., US 5,731,168). Multispecific antibodies can also be prepared by the following methods: engineering electrostatic manipulation effects to prepare antibody Fc-heterodimer molecules (WO 2009 / 089004); cross-linking two or more antibodies or fragments (see, e.g., US 4,676,980, and Brennan, M. et al., Science 229 (1985) 81-83); using leucine zippers to produce bispecific antibodies (see, e.g., Kostelny, S. A. et al., J. Immunol. 148 (1992) 1547-1553); using "diabody" technology to prepare bispecific antibody fragments (see, e.g., Holliger, P. et al., Proc. Natl. Acad. Sci. USA 90 (1993) 6444-6448); using single-chain Fv (scFv) dimers (Gruber, M. et al., J. Immunol. 152 (1994) 5368-5374); and preparing trispecific antibodies as described in Tutt, A. et al., J. Immunol. 147 (1991) 60-69.
[0143] The antibody or fragment may also be a multispecific antibody as described in WO 2009 / 080251, WO 2009 / 080252, WO 2009 / 080253, WO 2009 / 080254, WO 2010 / 112193, WO 2010 / 115589, WO 2010 / 136172, WO 2010 / 145792 or WO 2010 / 145793.
[0144] The antibody or fragment thereof may also be a multispecific antibody (also called "DutaFab") as disclosed in WO 2012 / 163520.
[0145] Bispecific antibodies are generally antibody molecules that specifically bind to two different, non-overlapping epitopes on the same antigen or to two epitopes on different antigens.
[0146] Different bispecific antibody formats are known.
[0147] Exemplary bispecific antibody formats in which the methods as reported herein can be used are:
[0148] -Domain exchange format: a multispecific IgG antibody comprising a first Fab fragment and a second Fab fragment, wherein in the first Fab fragment
[0149] a) only the CH1 and CL domains are replaced with each other (i.e. the light chain of the first Fab fragment comprises the VL and CH1 domains, and the heavy chain of the first Fab fragment comprises the VH and CL domains);
[0150] b) only the VH and VL domains are replaced with each other (i.e. the light chain of the first Fab fragment comprises the VH and CL domains, and the heavy chain of the first Fab fragment comprises the VL and CH1 domains); or
[0151] c) the CH1 and CL domains are replaced with each other and the VH and VL domains are replaced with each other (i.e. the light chain of the first Fab fragment comprises the VH and CH1 domains, and the heavy chain of the first Fab fragment comprises the VL and CL domains); and
[0152] The second Fab fragment comprises a light chain and a heavy chain, the light chain comprises a VL and a CL domain, and the heavy chain comprises a VH and a CH1 domain;
[0153] The domain exchange antibody may comprise a first heavy chain comprising a CH3 domain and a second heavy chain comprising a CH3 domain, wherein the two CH3 domains are engineered in a complementary manner by respective amino acid substitutions to support heterodimerization of the first heavy chain and the modified second heavy chain, e.g. as disclosed in WO 96 / 27011, WO 98 / 050431, EP1870459, WO 2007 / 110205, WO 2007 / 147901, WO 2009 / 089004, WO 2010 / 129304, WO 2011 / 90754, WO 2011 / 143545, WO 2012 / 058768, WO 2013 / 157954, or WO 2013 / 096291 (incorporated herein by reference);
[0154] - One-armed single-chain format (= one-armed single-chain antibody): an antibody comprising a first binding site that specifically binds to a first epitope or antigen and a second binding site that specifically binds to a second epitope or antigen, whereby the individual chains are as follows:
[0155] -Light chain (variable light chain domain + light chain kappa constant domain)
[0156] - Combined light chain / heavy chain (variable light chain domain + light chain constant domain + peptide linker + variable heavy chain domain + CH1 + hinge + CH2 + CH3 with knob mutation)
[0157] - Heavy chain (variable heavy chain domain + CH1 + hinge + CH2 + CH3 with hole mutation);
[0158] - Two-armed single-chain format (= two-armed single-chain antibody): an antibody comprising a first binding site that specifically binds to a first epitope or antigen and a second binding site that specifically binds to a second epitope or antigen, whereby the individual chains are as follows:
[0159] - Combined light chain / heavy chain 1 (variable light chain domain + light chain constant domain + peptide linker + variable heavy chain domain + CH1 + hinge + CH2 + CH3 with hole mutation)
[0160] - Combined light chain / heavy chain 2 (variable light chain domain+light chain constant domain+peptide linker+variable heavy chain domain+CH1+hinge+CH2+CH3 with knob mutation);
[0161] - Common light chain bispecific format (= common light chain bispecific antibody): an antibody comprising a first binding site that specifically binds to a first epitope or antigen and a second binding site that specifically binds to a second epitope or antigen, whereby the individual chains are as follows:
[0162] -Light chain (variable light chain domain + light chain constant domain)
[0163] -Heavy chain 1 (variable heavy chain domain + CH1 + hinge + CH2 + CH3 with hole mutation)
[0164] - Heavy chain 2 (variable heavy chain domain + CH1 + hinge + CH2 + CH3 with knob mutation).
[0165] In one embodiment of all aspects and embodiments of the invention the bispecific antibody is a domain swapped antibody.
[0166] In one embodiment of all aspects and embodiments of the invention, the bispecific antibody is a one-armed single chain antibody.
[0167] In one embodiment of all aspects and embodiments of the invention, the bispecific antibody is a two-armed single chain antibody.
[0168] In one embodiment of all aspects and embodiments of the invention the bispecific antibody is a common light chain bispecific antibody.
[0169] Surface plasmon resonance method of the prior art
[0170] The kinetic binding parameters of the antibodies to the corresponding antigen can be studied, for example, by surface plasmon resonance using a BIAcore instrument (GE Healthcare Biosciences AB, Uppsala, Sweden).
[0171] Briefly, for affinity measurement, anti-IgG antibodies (eg, anti-human IgG or anti-mouse IgG antibodies) were immobilized on a CM5 chip via amine coupling for capture and presentation of the corresponding antibodies to be analyzed.
[0172] For example, approximately 2000-12000 response units (RU) of 10-30 μg / ml anti-IgG antibody are coupled to some detection points of the flow cell of a CM5 sensor chip at pH 5.0 and a flow rate of 10-30 μl / min in a BIAcore B4000 instrument (for example, detection points 1 and 5 are active detection points, detection points 2 and 4 are reference detection points, or detection points 1 and 2 are reaction detection points, detection points 3 and 4 are reference detection points, etc.): using an amine coupling kit provided by GE Healthcare.
[0173] Binding was measured at 25°C (or alternatively at different temperatures ranging from 12°C to 37°C) in HBS buffer (HBS-P (10 mM HEPES, 150 mM NaCl, 0.005% Tween 20, pH 7.4), or HBS-EP+ (0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, 0.05% v / v surfactant PS20, pH 7.4), or HBS-ET (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% w / v Tween 20)).
[0174] Thereafter, antibodies were injected at concentrations ranging from 10 nM to 1 μM for 30 seconds and bound to the reaction detection point of each flow cell.
[0175] The corresponding antigen was then added to the solution at various concentrations, such as 144 nM, 48 nM, 16 nM, 5.33 nM, 1.78 nM, 0.59 nM, 0.20 nM and 0 nM, depending on the affinity of the antibody.
[0176] Association was measured by injecting antigen at a flow rate of 10-30 μl / min for 20 seconds to 10 minutes.
[0177] Dissociation was measured by washing the chip surface with the corresponding buffer for 3-10 minutes.
[0178] K was estimated using the 1:1 Langmuir binding model using the manufacturer's software and instructions. D Negative control data (e.g., buffer curve) were subtracted from the sample curves for correction of system-inherent baseline drift and noise signal reduction.
[0179] Method according to the invention
[0180] The increasing complexity of novel biotherapeutics such as bispecific antibodies or fusion proteins poses new challenges for functional characterization. Compared to standard antibodies, bispecific monoclonal antibodies require consideration of two separate interactions.
[0181] Herein, we report a novel SPR-based binding assay for measuring the avidity-based binding strength (ie, gain in binding affinity over avidity-based binding) of at least a bispecific antibody for simultaneous binding to its two targets / antigens.
[0182] The present invention is based at least in part on the discovery that by using a surface plasmon resonance-based method, avidity-based binding strength can be determined separately from affinity-based binding effects, wherein the two antigens are immobilized on a chip surface as bispecific molecules, i.e., using immobilized bispecific antigens, e.g., as bispecific Fc fusions.
[0183] Prior to the present invention, it was not possible to determine / measure the affinity-based activity of bispecific binders, such as bispecific antibodies. Determining the binding of separate monospecific binding sites only provides separate binding affinity values but does not allow for obtaining binding avidity values. This is also the case when applying an antigen mixture to a sensor surface to which a bispecific binder (e.g., a bispecific antibody) has been immobilized.
[0184] Furthermore, prior to the present invention, it was not possible to determine / measure a separate affinity-based binding strength (i.e., a defined affinity binding value). For example, the use of a sensor surface with a random distribution of antigens does not allow for the determination / measurement of a defined affinity-based binding strength, since the results obtained are influenced by affinity binding. Although the heterogeneity of the interaction decreases with increasing capture reagent density (i.e., immobilization level) on the chip surface, homogeneous interactions on a randomly distributed chip can only be achieved at high density (response level) (i.e., antigen immobilization level), at which a kinetic assessment of the binding interaction is not possible.
[0185] Therefore, in an SPR setup where individual antigens are randomly immobilized, i.e., with an inhomogeneous distribution of the different antigens, there will be antibodies that bind only one antigen because the two antigens are too far apart. The result of this non-defined, non-simultaneous binding is a mixture of defined affinity binding and avidity binding (see Figure 2 A).
[0186] In contrast, in an SPR setup with defined immobilization of linked antigens according to the invention, i.e. with a homogeneous distribution of different antigens, the antibody will bind both antigens simultaneously, since the two antigens are appropriately spaced. This defined simultaneous binding allows the determination of affinity binding ( Figure 2 B) Furthermore, the bispecific antigens showed homogeneous and avid interactions at any immobilization level.
[0187] The present invention is based, at least in part, on the discovery that by presenting at least two antigens of a bispecific binder in covalently linked form on the surface of an SPR chip, the affinity achieved by simultaneous bispecific binding can be determined.
[0188] The present invention is further based at least in part on the discovery that using the SPR assay according to the present invention, the affinity-driven selectivity gain (ADSG) of at least a bispecific binder can be determined. This concept allows the selection of at least a bispecific binder with increased target specificity, thereby reducing off-target binding and side effects.
[0189] It has been discovered that by determining and comparing the dissociation constant of at least a bispecific binder (sample) and its respective target to the dissociation constant of the bispecific target, the affinity gain provided by binding simultaneously at all valencies can be assessed.
[0190] One aspect of the invention is a method for determining the avidity-based binding strength of at least a bispecific binder comprising a first binding site that specifically binds to a first antigen and a second binding site that specifically binds to a second antigen, the method comprising the steps of:
[0191] - determining the affinity-based binding strength of at least the bispecific binder based on a change in a surface plasmon resonance signal obtained by applying a solution comprising at least the bispecific binder to a solid phase conjugated to the first antigen-second antigen fusion polypeptide.
[0192] When applying standard methods known in the art, it is not possible to determine the affinity with which at least a bispecific antibody binds simultaneously to its two antigens, since the results obtained are not conclusive.
[0193] Figure 3 The surface of an SPR chip that is generally used to determine the affinity binding of at least a bispecific antibody is schematically shown. The two antigens are immobilely unconnected. In order to capture, each antigen comprises a label and is captured using an anti-label antibody. Thus, a random surface is generated, which comprises a mixture of anti-label antibodies with only the first antigen or only the second antigen or with two antigens. Therefore, a homogeneous surface is not obtained, but an uneven distribution of antigens on the surface is obtained.
[0194] The consequence of this uneven distribution of antigen on the SPR chip surface is that homogeneous binding cannot be observed. Figure 4 Different binding modes resulting from the uneven distribution of antigens on the chip surface are shown: 1 and 2: binding with only one binding site; 3: binding to a single complex with two binding sites simultaneously; 4: binding to two different complexes with two binding sites simultaneously. Therefore, at most, up to 50% of the bispecific antibodies can be expected to bind simultaneously and up to 25% of the antibodies to a single bispecific antigen complex.
[0195] Thus, an inhomogeneous distribution of the antigen on the surface leads to a mixing of binding events of at least the bispecific antibody, which in turn leads to inconclusive sensorgrams. Figure 5 The overlap of two sensorgrams obtained under the same conditions using the same bispecific antibody, differing only in the form of the antigens captured on the chip surface: one obtained using a mixture of antigens according to the reference method of the prior art, and the other obtained using a fusion polypeptide of the first and second antigens according to the method of the invention. As can be seen, the sensorgrams are clearly different. Homogeneous and analyzable response curves were obtained only in the sensorgrams obtained using a fusion polypeptide of the first and second antigens according to the method of the invention ( Figure 6 ). In the sensorgrams obtained using the reference method, different, overlapping dissociation processes (and kinetics) can be seen, which lead to unanalyzable response curves.
[0196] from Figure 7 (and Figure 5 same experimental conditions; the difference lies only in the immobilized form of the antigen) it can be seen that the heterogeneous dissociation kinetics obtained with the antigen mixture is a mixed result of avidity binding and affinity binding events, since the same sensorgram is obtained using only one antigen.
[0197] Figure 5 and 7 The sensorgrams in the figure were obtained at low capture levels of 5-15 RU. Increasing the capture level, for example to 50-120 RU ( Figure 8 ) or even 300-600RU( Fig. 9 ), does not change the sensorgram.
[0198] The same results can be seen when analyzing the interaction using kinetic rate plots. As can be seen in Figure 10, only in case of applying the method according to the invention can unaffected affinity binding events be analyzed.
[0199] One aspect of the invention is a method for determining the avidity-based binding strength of at least a bispecific binder to a first antigen and a second antigen, the at least bispecific binder comprising a first binding site that specifically binds to the first antigen and a second binding site that specifically binds to the second antigen, the method comprising the steps of:
[0200] a) capturing the first antigen-second antigen fusion polypeptide on a solid phase and determining / measuring / confirming a first surface plasmon resonance response,
[0201] b) applying a solution comprising at least a bispecific binder to the solid phase of step a) to form a captured first antigen-second antigen fusion polypeptide-bispecific binder complex and determining / measuring / confirming a second surface plasmon resonance response,
[0202] c) determining / calculating the affinity-based binding strength of at least the bispecific binder for the first and second antigens from the difference between the first and second surface plasmon resonance responses.
[0203] One aspect of the invention is a method for determining the avidity-based binding strength of at least a bispecific binder to a first antigen and a second antigen, the at least bispecific binder comprising a first binding site that specifically binds to the first antigen and a second binding site that specifically binds to the second antigen, the method comprising the steps of:
[0204] a) capturing the first antigen-second antigen fusion polypeptide on a solid phase (and determining / measuring / confirming the baseline surface plasmon resonance response),
[0205] b) applying a first solution comprising at least a bispecific binder at a first concentration to the solid phase of step a) to form a captured first antigen-second antigen fusion polypeptide-bispecific binder complex and determining / measuring / confirming a first surface plasmon resonance response, (whereby the first surface plasmon resonance response is a change in the surface plasmon resonance response obtained by applying the bispecific binder to the solid phase relative to a baseline surface plasmon resonance response),
[0206] c) dissociating the captured first antigen-second antigen fusion polypeptide-bispecific binder complex and thereby regenerating the solid phase,
[0207] d) repeating steps b) and c) with at least a second solution comprising a second concentration of at least the bispecific binder and determining / measuring / confirming a second surface plasmon resonance response, whereby the first and second concentrations are different,
[0208] e) determining / calculating the affinity-based binding strength of at least the bispecific binder for the first and second antigen from the surface plasmon resonance response as determined in the previous step.
[0209] In one embodiment of all aspects and embodiments of the invention at least the bispecific binding partner is a bispecific antibody.
[0210] In one embodiment of all aspects and embodiments of the invention, the first antigen is at least a fragment of an epitope of said first antigen comprising the first binding site of the bispecific binder, and the second antigen is at least a fragment of an epitope of said second antigen comprising the second binding site of the bispecific binder.
[0211] In one embodiment of all aspects and embodiments of the invention the solid phase is a surface plasmon resonance chip.
[0212] One aspect of the invention is a fusion polypeptide of at least a first antigen and a second antigen of a bispecific binder.
[0213] This fusion protein according to the present invention is referred to herein as a "first antigen-second antigen fusion polypeptide".
[0214] In one embodiment of all aspects and embodiments of the invention, the fusion polypeptide according to the invention comprises as first antigen at least a fragment of a first antigen (comprising an epitope of at least the first binding site of the bispecific binder) and as second antigen at least a fragment of a second antigen (comprising an epitope of at least the second binding site of the bispecific binder).
[0215] In one embodiment of all aspects and embodiments of the invention, the fusion polypeptide according to the invention is a linear polypeptide wherein the first antigen is at the C-terminus and the second antigen is at the N-terminus, or vice versa. In one embodiment, the first antigen and the second antigen are linked by a peptide linker. In one embodiment, the peptide linker comprises a tag for fixation to a solid phase.
[0216] In one embodiment of all aspects and embodiments of the present invention, the fusion polypeptide is a heterodimeric polypeptide comprising a first polypeptide and a second polypeptide, the first polypeptide being a fusion polypeptide of a first antigen and a first antibody heavy chain Fc region polypeptide comprising a first set of heterodimerization mutations, the second polypeptide being a fusion polypeptide of a second antigen and a second antibody heavy chain Fc region polypeptide comprising a second set of heterodimerization mutations, the second set of heterodimerization mutations being complementary to the first set of heterodimerization mutations. In one embodiment, the first antigen and the second antigen are at the N-terminus of the corresponding first or second Fc region polypeptide. In one embodiment, one or both of the Fc region polypeptides comprise a tag for fixation to a solid phase. In one embodiment, the tag is located at the C-terminus of the corresponding Fc region polypeptide. In one embodiment, the Fc region is of human IgG1 isotype. In one embodiment, the first and second sets of heterodimerization mutations are T366W and T366S / L368A / Y407V, respectively, and vice versa. In one embodiment, the tag for fixation is on a histidine tag or biotin.
[0217] In one embodiment of all aspects and embodiments of the present invention, the fusion polypeptide is a heterodimeric polypeptide comprising a first polypeptide and a second polypeptide, the first polypeptide being a fusion polypeptide of a first antigen and a first antibody heavy chain constant region polypeptide comprising a first set of heterodimerization mutations, the second polypeptide being a fusion polypeptide of a second antigen and a second antibody heavy chain constant region polypeptide comprising a second set of heterodimerization mutations, the second set of heterodimerization mutations being complementary to the first set of heterodimerization mutations. In one embodiment, the first antigen and the second antigen are located at the N-terminus of the corresponding first or second constant region polypeptide. In one embodiment, one or both of the constant region polypeptides comprises a tag for fixation to a solid phase. In one embodiment, the tag is located at the C-terminus of the corresponding Fc region polypeptide. In one embodiment, the Fc region belongs to the human IgG1 isotype. In one embodiment, the first and second sets of heterodimerization mutations are T366W and T366S / L368A / Y407V, respectively, and vice versa. In one embodiment, the tag for fixation is on a histidine tag or biotin.
[0218] Thus, in general, one aspect of the invention is a heterodimeric fusion polypeptide comprising
[0219] i) a first proteinaceous portion, and
[0220] ii) a second proteinaceous portion,
[0221] in
[0222] - the first proteinaceous moiety and the second proteinaceous moiety are the first antigen and the second antigen of the at least bispecific antibody, the at least bispecific antibody comprising a first binding site that specifically binds to the first proteinaceous moiety and a second binding site that specifically binds to the second proteinaceous moiety,
[0223] - the first proteinaceous part is fused to the N-terminus of the Fc region polypeptide of the first antibody heavy chain of the IgG1 subtype,
[0224] - a second proteinaceous part is fused to the N-terminus of a second antibody heavy chain Fc region polypeptide of the IgG1 subtype,
[0225] - the first heavy chain Fc region polypeptide and the second heavy chain Fc region polypeptide form a disulfide-bonded heterodimer,
[0226] - one or both of the heavy chain Fc region polypeptides comprises a tag at its C-terminus for fixation to a solid phase, and
[0227] - the first Fc-region polypeptide and the second Fc-region polypeptide comprise the mutations T366W and T366S / L368A / Y407V, respectively.
[0228] This heterodimeric fusion polypeptide is a fusion polypeptide of at least the first antigen and the second antigen of the bispecific binder.
[0229] In one embodiment of all aspects and embodiments of the invention, the fusion polypeptide according to the invention comprises only one (ie exactly one) first antigen and only one (ie exactly one) second antigen.
[0230] In one embodiment of all aspects and embodiments of the invention, the first antigen and the second antigen are not the same polypeptide.
[0231] In one embodiment of all aspects and embodiments of the invention the first proteinaceous moiety and the second proteinaceous moiety are not from the same polypeptide.
[0232] One aspect of the present invention is the use of a fusion polypeptide of a first antigen and a second antigen of at least a bispecific binder according to the present invention in a surface plasmon resonance method to determine the affinity-based binding strength of the at least bispecific binder to the first and second antigens, the binder comprising a first binding site that specifically binds to the first antigen and a second binding site that specifically binds to the second antigen.
[0233] One aspect of the invention is an affinity chromatography column comprising a fusion polypeptide of at least the first antigen and the second antigen of the bispecific binder according to the invention, the fusion polypeptide serving as chromatographic ligand.
[0234] One aspect of the invention is a method for separating / purifying at least a bispecific binder having avidity-based binding to a first and a second antigen, comprising a first binding site that specifically binds to the first antigen and a second binding site that specifically binds to the second antigen, from bispecific binders that do not have avidity-based binding to the same first and second antigens, the method comprising the steps of:
[0235] a) applying a solution comprising at least a bispecific binder with and without affinity-based binding to a first and a second antigen to an affinity chromatography column according to the invention,
[0236] b) recovering from the column at least the bispecific binder having affinity-based binding to the first and second antigens, thereby separating / purifying the at least bispecific binder from bispecific binders that do not have affinity-based binding to the same first and second antigens.
[0237] One aspect of the invention is a method for purifying (from product-related and / or process-related impurities) an at least bispecific binder having affinity-based binding to a first antigen and a second antigen, the at least bispecific binder comprising a first binding site that specifically binds to the first antigen and a second binding site that specifically binds to the second antigen, the method comprising the steps of:
[0238] a) applying a solution comprising the at least bispecific binder having affinity-based binding to a first antigen and a second antigen (and process-related and / or product-related impurities) to an affinity chromatography column according to the invention,
[0239] b) optionally washing the column, wherein the at least bispecific binder having avidity-based binding to the first antigen and the second antigen remains bound to the column, and
[0240] c) recovering at least the bispecific binder having affinity-based binding to the first antigen and the second antigen from the column and thereby purifying the bispecific binder (from product-related and / or process-related impurities).
[0241] A surface plasmon resonance chip comprises a fusion polypeptide of at least a first antigen and a second antigen of a bispecific binder according to the present invention, wherein the fusion polypeptide is immobilized in at least one flow cell.
[0242] A method for producing a surface plasmon resonance chip, the surface plasmon resonance chip comprising a fusion polypeptide of at least a first antigen and a second antigen of a bispecific binder according to the present invention, the fusion polypeptide being immobilized in at least one flow cell, the method comprising the following steps:
[0243] - Immobilizing a fusion polypeptide of at least the first antigen and the second antigen of the bispecific binder according to the invention directly or via a specific binding pair in at least one flow cell of a surface plasmon resonance chip.
[0244] One aspect of the invention is a method for determining the avidity-based binding strength of at least a bispecific binder comprising a first binding site that specifically binds to a first antigen and a second binding site that specifically binds to a second antigen, the method comprising the steps of:
[0245] - determining at least the affinity-based binding strength of the bispecific binder based on a change in a surface plasmon resonance signal obtained by applying a solution comprising the first antigen-second antigen fusion polypeptide to a solid phase conjugated to the bispecific binder.
[0246] One aspect of the invention is a method for determining the avidity-based binding strength of at least a bispecific binder to a first antigen and a second antigen, the at least bispecific binder comprising a first binding site that specifically binds to the first antigen and a second binding site that specifically binds to the second antigen, the method comprising the steps of:
[0247] a) capturing at least the bispecific binder on a solid phase and determining / measuring / confirming a first surface plasmon resonance response,
[0248] b) applying a solution comprising the first antigen-second antigen fusion polypeptide to the solid phase of step a) to form a captured first antigen-second antigen fusion polypeptide-bispecific binder complex and determining / measuring / confirming a second surface plasmon resonance response,
[0249] c) determining / calculating the affinity-based binding strength of at least the bispecific binder for the first and second antigens from the difference between the first and second surface plasmon resonance responses.
[0250] One aspect of the invention is a method for determining the avidity-based binding strength of at least a bispecific binder to a first antigen and a second antigen, the at least bispecific binder comprising a first binding site that specifically binds to the first antigen and a second binding site that specifically binds to the second antigen, the method comprising the steps of:
[0251] a) capturing at least the bispecific binder on a solid phase (and determining / measuring / confirming a baseline surface plasmon resonance response),
[0252] b) applying a first solution comprising a first concentration of the first antigen-second antigen fusion polypeptide to the solid phase of step a) to form a captured first antigen-second antigen fusion polypeptide-bispecific binder complex and determining / measuring / confirming a first surface plasmon resonance response, (whereby the first surface plasmon resonance response is a change in the surface plasmon resonance response obtained by applying the first antigen-second antigen fusion polypeptide to the solid phase relative to a baseline surface plasmon resonance response),
[0253] c) dissociating the captured first antigen-second antigen fusion polypeptide-bispecific binder complex and thereby regenerating the solid phase,
[0254] d) repeating at least steps b) and c) with a second solution comprising a second concentration of the first antigen-second antigen fusion polypeptide and determining / measuring / confirming a second surface plasmon resonance response, wherein all concentrations are different,
[0255] e) determining / calculating the affinity-based binding strength of at least the bispecific binder for the first and second antigen from the surface plasmon resonance response as determined in the previous step.
[0256] In one embodiment of all aspects and embodiments of the invention at least the bispecific binding partner is a bispecific antibody.
[0257] In one embodiment of all aspects and embodiments of the invention, the first antigen is at least a fragment of an epitope of said first antigen comprising at least the first binding site of the bispecific binder, and the second antigen is at least a fragment of an epitope of said second antigen comprising at least the second binding site of the bispecific binder.
[0258] In one embodiment of all aspects and embodiments of the invention the solid phase is a surface plasmon resonance chip.
[0259] Quality assessment of samples relative to reference
[0260] In this setup, an antibody capable of avid binding will always bind to both specificities because after the initial first binding event, the local concentration of the second binding partner is greatly increased due to the close proximity. Avidity effects have a dramatic impact on the dissociation rate constant, kd, of the antibody from its antigen, so relative activity can be assessed in relation to the potency of the antibody simply by reading out a single response during the dissociation phase of the SPR measurement. Since kd affects the equilibrium concentration, this approach can also be exploited by ELISA or similar methods to assess the bispecific binding ability of an antibody to all of its targets.
[0261] Therefore, according to one aspect of the present invention is a method for assessing the quality / purity / homogeneity of a sample comprising at least a bivalent bispecific antibody, the method comprising the following steps:
[0262] - applying solutions containing a covalent fusion polypeptide comprising a first antigen of the bivalent bispecific antibody at one end and a second antigen of the bivalent bispecific antibody at a different second end to the SPR chip on which the bivalent bispecific antibody has been immobilized at different concentrations, respectively, and then monitoring the SPR signal,
[0263] as well as
[0264] - comparing the determined readings with readings of a reference sample (obtained in the same way) and thereby determining the quality / purity / homogeneity of the sample comprising the at least bivalent bispecific antibody,
[0265] wherein the at least bivalent bispecific antibody comprises a first binding site that specifically binds to a first non-antibody antigen and a second binding site that specifically binds to a different second non-antibody antigen.
[0266] In one embodiment, the method comprises the following steps:
[0267] - applying a solution containing a covalent fusion polypeptide comprising a first antigen of the bivalent bispecific antibody at one end and a second antigen of the bivalent bispecific antibody at a different second end to the SPR chip on which the bivalent bispecific antibody has been immobilized at at least two different concentrations, respectively, and then monitoring the SPR signal,
[0268] - Plot the binding response (in resonance units) against the corresponding sample concentration,
[0269] - fit the data points of the obtained plot using a 2-parameter line fit and determine the y-intercept as the readout,
[0270] - comparing the determined readings with the readings of a reference sample (analyzed in the same way) by means of a parallel line transformation and thereby determining the quality / purity / homogeneity of the sample comprising the at least bivalent bispecific antibody,
[0271] wherein the at least bivalent bispecific antibody comprises a first binding site that specifically binds to a first non-antibody antigen and a second binding site that specifically binds to a different second non-antibody antigen.
[0272] The method is based on SPR assay.
[0273] In the first step, the antibody specifically binds to the antibody in question, for example, if the antibody in question contains mutations LALA (L234A / L235A) and PG (P329G) in its Fc region, the antibody specifically binding to the LALA mutation or PG mutation in the Fc region of the sample antibody is fixed to the SPR sensor chip according to the manufacturer's instructions. In this example, a bivalent bispecific antibody (denoted as LALAPG in this article; according to Kabat numbering) in the domain exchange form with mutations P329G and L234A / L235A in the Fc region is used. Similarly, any other mutation in the Fc region can be used as long as there is a capture reagent that specifically binds to it.
[0274] At least 16000 RU ("response binding") should be immobilized to ensure that antigen capture is not limited by immobilization. The reference control flow cell was treated in the same manner. Finally, both surfaces were blocked. The preferred immobilization buffer is HBS-EP+ (10 mM HEPES, 150 mM NaCl pH 7.4, GE Healthcare).
[0275] Second, a bivalent bispecific antibody was injected.
[0276] Third, Antigen 1 - Antigen 2 Fc region fusion according to the present invention was injected onto the second flow cell at different concentrations.
[0277] SPR signal is detected.The binding response (resonance unit, RU) of antigen 1-antigen 2 Fc region fusion is related to the amount of bivalent bispecific antibody, and is mapped according to the sample concentration range used.The linear graph obtained is analyzed by appropriate computer software (such as XLfit4, IDBS software), and the software fits 2 parameter lines, so the y-axis intercept can be determined, which is equivalent to biological binding activity (=efficacy) readings.Using, for example, parallel line transformation, the relative efficacy (=reportable efficacy) of the sample compared with the antibody reference standard can be determined.
[0278] Antigen 1 and Antigen 2 bind simultaneously to the captured bivalent bispecific antibody. The target binding response is used as the final assay readout.
[0279] The above method is intended to meet the potency release assay criteria of USP 1032, as disclosed by Gassner et al. (Gassner, C., et al. J. Pharm. Biomed. Anal. 102 (2015) 144-149). However, if it is not necessary to meet the USP 1032 criteria, it is sufficient to measure a single concentration and plot it against a calibration curve of a reference standard.
[0280] In an alternative arrangement, according to one aspect of the invention is a method for assessing the quality / purity / homogeneity of a sample comprising at least a bivalent bispecific antibody, the method comprising the following steps:
[0281] - applying solutions containing the bivalent bispecific antibody at different concentrations to an SPR chip on which a covalent fusion polypeptide has been immobilized, the covalent fusion polypeptide comprising a first antigen of the bivalent bispecific antibody at one end and a second antigen of the bivalent bispecific antibody at a different second end, respectively, and then monitoring the SPR signal,
[0282] as well as
[0283] - comparing the determined readings with readings of a reference sample (obtained in the same way) and thereby determining the quality / purity / homogeneity of the sample comprising the at least bivalent bispecific antibody,
[0284] wherein the at least bivalent bispecific antibody comprises a first binding site that specifically binds to a first non-antibody antigen and a second binding site that specifically binds to a different second non-antibody antigen.
[0285] In one embodiment, the method comprises the following steps:
[0286] - applying a solution comprising the bivalent bispecific antibody at at least two different concentrations to an SPR chip having a covalent fusion polypeptide immobilized thereon, the covalent fusion polypeptide comprising a first antigen of the bivalent bispecific antibody at one end and a second antigen of the bivalent bispecific antibody at a different second end, respectively, and then monitoring the SPR signal,
[0287] - Plot the binding response (in resonance units) against the corresponding sample concentration,
[0288] - fit the data points of the obtained plot using a 2-parameter line fit and determine the y-intercept as the readout,
[0289] - comparing the determined readings with the readings of a reference sample (analyzed in the same way) by means of a parallel line transformation and thereby determining the quality / purity / homogeneity of the sample comprising the at least bivalent bispecific antibody,
[0290] wherein the at least bivalent bispecific antibody comprises a first binding site that specifically binds to a first non-antibody antigen and a second binding site that specifically binds to a different second non-antibody antigen.
[0291] The method is based on SPR assay.
[0292] In the first step, the antibody specifically binds to the antigen 1-antigen 2 Fc region fusion, for example, if the antigen 1-antigen 2 Fc region fusion contains mutations LALA (L234A / L235A) and PG (P329G) in its Fc region, the antibody specifically bound to the LALA mutation or PG mutation in the sample antibody Fc region is fixed to the SPR sensor chip according to the manufacturer's instructions. At least 16000RU ("response binding") should be fixed to ensure that antibody capture is not limited by immobilization. The reference control flow cell is processed in the same manner. Finally, both surfaces are blocked. The preferred fixed buffer is HBS-EP+ (10mM HEPES, 150mM NaCl pH 7.4, GE Healthcare).
[0293] Next, the Antigen 1-Antigen 2 Fc region fusion according to the present invention was injected.
[0294] Third, the bivalent bispecific antibody was injected at different concentrations.
[0295] SPR signal is detected.The binding response (resonance unit, RU) of bivalent bispecific antibody is related to the amount of antigen 1-antigen 2 Fc region fusion body, and is mapped according to the sample concentration range used.The linear graph obtained is analyzed by appropriate computer software (such as XLfit4, IDBS software), and the software fits 2 parameter lines, so the y-axis intercept can be determined, which is equivalent to biological binding activity (=efficacy) reading.Using, for example, parallel line transformation, the relative efficacy (=reportable efficacy) of the sample compared with the antibody reference standard can be determined.
[0296] Captured Antigen 1 and Antigen 2 are simultaneously bound to the bivalent bispecific antibody. The target binding response is used as the final assay readout.
[0297] The above method is intended to meet the potency release assay criteria of USP 1032, as disclosed by Gassner et al. (Gassner, C., et al. J. Pharm. Biomed. Anal. 102 (2015) 144-149). However, if it is not necessary to meet the USP 1032 criteria, it is sufficient to measure a single concentration and plot it against a calibration curve of a reference standard.
[0298] Overview
[0299] At least part of the present invention relates to:
[0300] 1. A method for determining the affinity-based binding strength of an at least bivalent bispecific antibody to its first antigen and a second antigen, the method comprising
[0301] - determining the avidity-based binding strength of the bivalent, bispecific antibody according to a surface plasmon resonance signal obtained by applying a solution comprising the bivalent, bispecific antibody to a solid phase conjugated to a covalent fusion polypeptide comprising the first antigen at one end and the second antigen at a different, second end, and subsequently monitoring the SPR signal,
[0302] wherein the at least bivalent bispecific antibody comprises a first binding site that specifically binds to a first non-antibody antigen and a second binding site that specifically binds to a different second non-antibody antigen.
[0303] 2. The method according to claim 1, further comprising the following steps:
[0304] a) capturing the first antigen-second antigen fusion polypeptide on a solid phase,
[0305] b) applying a first solution comprising a first concentration of the bivalent bispecific antibody to the solid phase of step a) to form a captured first antigen-second antigen fusion polypeptide-bivalent bispecific antibody complex and determining a first surface plasmon resonance response,
[0306] c) dissociating the captured first antigen-second antigen fusion polypeptide-bivalent bispecific antibody complex and thereby regenerating the solid phase,
[0307] d) repeating at least steps b) and c) with a second solution comprising said bivalent, bispecific antibody at a second concentration and determining a second surface plasmon resonance response, wherein all concentrations are different,
[0308] e) determining the avidity-based binding strength of said at least bivalent bispecific antibody to said first antigen and said second antigen according to said surface plasmon resonance response as determined in the previous step.
[0309] 3. A method according to any one of items 1 to 2, wherein each covalent fusion polypeptide comprising a first antigen at one end and a second antigen at a different second end is conjugated to a solid phase respectively.
[0310] 4. A method according to any one of items 1 to 3, wherein the first antigen is at least a fragment of an epitope of the first antigen comprising the first binding site of the bivalent bispecific antibody, and the second antigen is at least a fragment of an epitope of the second antigen comprising the second binding site of the bivalent bispecific antibody.
[0311] 5. The method according to any one of items 1 to 4, wherein the first antigen is different from the second antigen.
[0312] 6. A method according to any one of items 1 to 5, wherein the solid phase is a surface plasmon resonance chip.
[0313] 7. A method according to any one of items 1 to 6, wherein the first antigen-second antigen fusion polypeptide is a heterodimeric polypeptide comprising a first polypeptide and a second polypeptide, the first polypeptide is a fusion polypeptide of a first antigen and a first antibody heavy chain Fc region polypeptide comprising a first set of heterodimerization mutations, the second polypeptide is a fusion polypeptide of a second antigen and a second antibody heavy chain Fc region polypeptide comprising a second set of heterodimerization mutations, and the second set of heterodimerization mutations are complementary to the first set of heterodimerization mutations.
[0314] 8. A method according to item 7, wherein the first antigen and the second antigen are at the N-terminus of the corresponding first or second Fc region polypeptide.
[0315] 9. The method according to any one of items 1 to 8, wherein the first antigen-second antigen fusion polypeptide comprises a tag for fixation to a solid phase.
[0316] 10. The method according to item 9, wherein the tag is at the C-terminus of the corresponding Fc region polypeptide.
[0317] 11. A method according to any one of items 7 to 10, wherein the Fc region is of the human IgG1 isotype.
[0318] 12. A method according to any one of items 7 to 11, wherein the first and second groups of heterodimerization mutations are T366W and T366S / L368A / Y407V, respectively, or vice versa.
[0319] 13. A heterodimeric fusion polypeptide comprising
[0320] i) a first polypeptide, and
[0321] ii) a second polypeptide,
[0322] in
[0323] - the first polypeptide and the second polypeptide are the first antigen and the second antigen of a bispecific antibody, the bispecific antibody comprising a first binding site that specifically binds to the first polypeptide and a second binding site that specifically binds to the second polypeptide,
[0324] - the first polypeptide is fused to the N-terminus of the first antibody heavy chain Fc region polypeptide of the IgG1 subtype,
[0325] - the second polypeptide is fused to the N-terminus of the heavy chain Fc region polypeptide of the second antibody of the IgG1 subtype,
[0326] - the first heavy chain Fc region polypeptide and the second heavy chain Fc region polypeptide form a disulfide-bonded heterodimer,
[0327] - one or both of said heavy chain Fc region polypeptides comprises at its C-terminus a tag for fixation to a solid phase,
[0328] - said first Fc-region polypeptide and said second Fc-region polypeptide comprise the mutations T366W and T366S / L368A / Y407V, respectively, and
[0329] - said first antigen is different from said second antigen.
[0330] 14. Use of the heterodimeric fusion polypeptide according to item 13 for determining the affinity-based binding strength of a bispecific antibody to the first and second antigens in a surface plasmon resonance method, wherein the bispecific antibody comprises a first binding site that specifically binds to the first antigen and a second binding site that specifically binds to the second antigen.
[0331] 15. A method for purifying a bispecific antibody having affinity-based binding to a first antigen and a second antigen from product-related and / or process-related impurities, the bispecific antibody comprising a first binding site that specifically binds to the first antigen and a second binding site that specifically binds to the second antigen, the method comprising the steps of:
[0332] a) applying a solution comprising the bispecific antibody having avidity-based binding to a first antigen and a second antigen and process-related and / or product-related impurities to an affinity chromatography column comprising the heterodimeric fusion polypeptide according to item 13 as chromatographic ligand,
[0333] b) optionally washing the column, wherein the bispecific antibody having avidity-based binding to the first antigen and the second antigen remains bound to the column, and
[0334] c) recovering the bispecific antibody having affinity-based binding to the first antigen and the second antigen from the column and thereby purifying the bispecific antibody (from product-related and / or process-related impurities).
[0335] ***
[0336] The following examples and drawings are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It should be understood that modifications may be made to the procedures set forth without departing from the spirit of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0337] Figure 1 : Schematic representation of affinity-based binding and avidity-based binding.
[0338] Figure 2 : A: SPR setup with random immobilization of a mixture of antigens. In an SPR setup with random immobilization of individual antigens, i.e. with an inhomogeneous distribution of different antigens, there will be antibodies that bind to only one antigen, since the two antigens are too far apart, leading to a mixture of determined affinity binding and avidity binding.
[0339] B: SPR setup with undefined immobilization of linked antigens. In an SPR setup with defined immobilization of linked antigens, ie with a uniform distribution of different antigens, the antibody will bind to both antigens simultaneously, since the two antigens are appropriately spaced, leading to defined affinity binding.
[0340] Figure 3 : Schematic representation of the surface of an SPR chip obtained by immobilizing unattached antigens. For capture, each antigen contains a tag and is captured using anti-tag antibodies. This results in a random surface containing a mixture of anti-tag antibodies with only the first antigen, only the second antigen, or both antigens. Therefore, a homogenous surface is not obtained, but an inhomogeneous distribution of antigens on the surface.
[0341] Figure 4 :Different binding modes of bispecific antibodies caused by uneven distribution of antigens on the SPR chip surface:
[0342] 1 and 2: bind to only one binding site;
[0343] 3: Binds to a single complex simultaneously with two binding sites;
[0344] 4: Binds to two different complexes simultaneously with two binding sites.
[0345] Figure 5 : Overlay of SPR sensorgrams of two sensorgrams obtained under the same conditions using the same bispecific antibody, differing only in the form of the antigen captured on the chip surface:
[0346] Upload sensory image: obtained using antigen mixture;
[0347] Lower sensorgram: obtained using the fusion polypeptide according to the present invention;
[0348] Only in the sensorgrams obtained using the method according to the invention can homogeneous and analyzable response curves be obtained.
[0349] Fixed level 5-15RU.
[0350] Figure 6 :and Figure 5 The same sensorgram with additional annotations.
[0351] Figure 7 : Overlay of SPR sensorgrams of four sensorgrams obtained under the same conditions using the same bispecific antibody, differing only in the form of the antigen captured on the chip surface:
[0352] 1: antigen 1 only;
[0353] 2: Antigen 2 only;
[0354] 3: Antigen mixture;
[0355] 4: A fusion polypeptide according to the present invention;
[0356] Only in the sensorgrams obtained using the method according to the invention can homogeneous and analyzable response curves be obtained.
[0357] (and Figure 5 Same experimental conditions)
[0358] Figure 8 :and Figure 7 Same, but obtained at a fixed level of 50-120RU.
[0359] 1: antigen 1 only;
[0360] 2: Antigen 2 only;
[0361] 3: antigen mixture;
[0362] 4: A fusion polypeptide according to the present invention;
[0363] Only in the sensorgrams obtained using the method according to the invention can homogeneous and analyzable response curves be obtained.
[0364] Fig. 9 :and Figure 7 Same, but obtained at a fixed level of 300-600RU.
[0365] 1: antigen 1 only;
[0366] 2: Antigen 2 only;
[0367] 3: antigen mixture;
[0368] 4: A fusion polypeptide according to the present invention;
[0369] Only in the sensorgrams obtained using the method according to the invention can homogeneous and analyzable response curves be obtained.
[0370] Figure 10: Kinetic rate diagram of the interaction:
[0371] A: Antigen 1 only;
[0372] B: Antigen 2 only;
[0373] C: fusion polypeptide according to the present invention;
[0374] The same bispecific antibody was used.
[0375] Examples
[0376] Equipment and reagents
[0377] All SPR experiments were performed on a BIAcore T200 instrument (GE Healthcare) at 25° C. If not mentioned otherwise, antibodies were manufactured by Roche Diagnostics GmbH (Mannheim, Germany).
[0378] Recombinant DNA technology
[0379] Standard methods were used to manipulate DNA, such as described in Sambrook, J. et al., Molecular Cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Molecular biology reagents were used according to the manufacturers' instructions.
[0380] DNA sequencing
[0381] DNA sequences were determined by double-strand sequencing performed at MediGenomix GmbH (Martinsried, Germany) or SequiServe GmbH (Vaterstetten, Germany).
[0382] Example 1
[0383] Expression vectors, expression and purification
[0384] Expression vector
[0385] To express the polypeptide / antibody, an expression plasmid for transient expression (eg in HEK293) is used.
[0386] In addition to the antibody / peptide expression cassette, the vector also contains:
[0387] - an origin of replication, which allows replication of the plasmid in E. coli, and
[0388] -β-lactamase gene, which confers ampicillin resistance in Escherichia coli.
[0389] The transcription unit of the antibody gene consists of the following elements:
[0390] - Unique restriction site at the 5' end,
[0391] - the immediate early enhancer and promoter from human cytomegalovirus,
[0392] - followed by the intron A sequence,
[0393] - the 5' untranslated region of a human antibody gene,
[0394] - an immunoglobulin heavy chain signal sequence,
[0395] - Corresponding antibody chain encoding nucleic acid
[0396] - a 3' untranslated region having a polyadenylation signal sequence, and
[0397] - Unique restriction site at the 3' end.
[0398] Fusion genes encoding antibodies and fusion polypeptides as described herein are produced by PCR and / or gene synthesis, and the fusion genes are assembled by, for example, connecting corresponding nucleic acid segments using unique restriction sites in corresponding vectors through known recombination methods and techniques. The nucleotide sequence of the subclone is verified by DNA sequencing. In order to perform transient transfection, a large amount of plasmids (Nucleobond AX, Macherey-Nagel) are prepared from transformed Escherichia coli cultures by plasmid preparation.
[0399] Cell culture technology
[0400] Standard cell culture techniques as described in Current Protocols in Cell Biology (2000), Bonifacino, JS, Dasso, M., Harford, JB, Lippincott-Schwartz, J. and Yamada, KM (eds.), John Wiley & Sons, Inc, were used.
[0401] The bispecific antibody and fusion polypeptide were expressed by transient co-transfection of the corresponding expression plasmids in HEK293-F cells growing in suspension as described below.
[0402] Transient transfection in HEK293 system
[0403] All bispecific antibodies and fusion polypeptides were produced by transient transfection of 293F cells using the Freestyle system (ThermoFisher). Here, 293F cells were cultured in F17 medium, transfected with 293Free (Novagen), and fed with VPA 4mM and Feed 7 after 4 hours, and 0.6% glucose after 16h. In addition, Expi293F TM Expression system kit (ThermoFisher). TM Cells in Expi293 TM The cells were cultured in expression medium and ExpiFectamine was used according to the manufacturer's instructions. TM The cells were transfected using the 293 transfection kit. After 7 days, the cell supernatant was harvested and purified using standard methods.
[0404] Protein determination
[0405] The protein concentration of purified antibodies and derivatives was determined by measuring the optical density (OD) at 280 nm using the molar extinction coefficient calculated based on the amino acid sequence according to Pace, et al., Protein Science, 1995, 4, 2411-1423.
[0406] Determination of antibody concentration in supernatant
[0407] The concentration of the antibody in the cell culture supernatant was estimated by immunoprecipitation with protein A agarose beads (Roche). 60 μL protein A agarose beads were washed three times in TBS-NP40 (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Nonidet-P40). Subsequently, 1-15 mL of cell culture supernatant was applied to the protein A agarose beads pre-equilibrated in TBS-NP40. After incubation at room temperature for 1 hour, the beads were washed once with 0.5 mL TBS-NP40 on Ultrafree-MC-filter column (Amicon), washed twice with 0.5 mL 2x phosphate buffered saline (2x PBS, Roche), and briefly washed four times with 0.5 mL 100 mM sodium citrate of pH 5.0. The supernatant was added with 35 μL of PBS and the supernatant was added with 1% PBS. The supernatant was added with 1% PBS and the supernatant was added with 1% PBS. The supernatant was added with 1% PBS and the supernatant was added with 1% PBS. LDS sample buffer (Invitrogen) was used to elute the bound antibody. The sample reducing agent was mixed or left unreduced and heated at 70°C for 10 minutes. Thus, 5-30 μl was applied to 4-12% Bis-Tris SDS-PAGE (Invitrogen) (non-reducing SDS-PAGE was performed using MOPS buffer and Reducing SDS-PAGE was performed using MES buffer supplemented with antioxidant electrophoresis buffer (Invitrogen) and stained with Coomassie blue.
[0408] The concentration of antibodies and derivatives in cell culture supernatants was quantitatively measured by affinity HPLC chromatography. In short, cell culture supernatants containing antibodies and derivatives bound to protein A were applied to 200mM KH2PO4, 100mM sodium citrate, Applied Biosystems Poros A / 20 posts in pH 7.4, and eluted from matrix with 200mM NaCl, 100mM citric acid, pH 2.5 on an Agilent HPLC 1100 system. The protein eluted was quantitatively measured by UV absorbance and peak area integration. The standard IgG1 antibody of purification was used as a standard.
[0409] Alternatively, the concentration of antibodies and derivatives in cell culture supernatants was measured by Sandwich-IgG-ELISA. Briefly, StreptaWell High Bind Streptavidin A-96 well microtiter plates (Roche) were incubated with 100 μL / well of 0.1 μg / mL biotinylated anti-human IgG capture molecule F(ab')2<h-Fcγ> BI (Dianova) was coated at room temperature for 1 hour or overnight at 4°C, followed by washing three times with 200 μL / well of PBS, 0.05% Tween (PBST, Sigma). 100 μL / well of cell culture supernatant containing a dilution series of the corresponding antibody in PBS (Sigma) was added to the wells and incubated on a microtiter plate shaker at room temperature for 1-2 hours. The wells were washed three times with 200 μL / well of PBST and 100 μl of 0.1 μg / mL F(ab')2<hFcγ> POD (Dianova) was used as the detection antibody and bound antibodies were detected on a microtiter plate shaker at room temperature for 1-2 hours. Unbound detection antibodies were washed three times with 200 μL / well of PBST and bound detection antibodies were detected by adding 100 μL ABTS / well. Absorbance measurements were performed at a measurement wavelength of 405 nm (reference wavelength was 492 nm) on a Tecan Fluor spectrometer.
[0410] Protein purification
[0411] Protein is purified from filtered cell culture supernatant with reference to standard protocol. In brief, antibody is applied to protein A agarose column (GE healthcare) and washed with PBS. Elution of antibody is achieved at pH 2.8, and sample is neutralized immediately afterwards. Aggregated protein is separated from monomeric antibody by size exclusion chromatography (Superdex 200, GE Healthcare) in PBS or in 20mM histidine, 150mM NaCl pH 6.0. Monomeric antibody fractions are merged, concentrated (if necessary) using, for example, MILLIPOREAmicon Ultra (30MWCO) centrifugal concentrators, frozen and stored at -20 ° C or -80 ° C. Samples are provided for example to carry out subsequent protein analysis and analysis characterization by SDS-PAGE, size exclusion chromatography (SEC) or mass spectrometry.
[0412] SDS-PAGE
[0413] Use according to the manufacturer's instructions Precast gel system (Invitrogen). Specifically, 10% or 4-12% Bis-TRIS precast gel (pH 6.4) and MES (reducing gel, with Antioxidant electrophoresis buffer additive) or MOPS (non-reducing gel) electrophoresis buffer.
[0414] Example 2
[0415] Determination procedure
[0416] BIAcore T200 CM5 sensor chips were prepared by immobilizing approximately 3000–5000 RU of anti-HIS antibody (GE Healthcare: His Capture Kit; No. 28995056) on flow cells three and four using standard amine coupling (GE Healthcare: Amine Coupling Kit, Type 1; No. BR100050) according to the manufacturer's instructions.
[0417] All sample cycles and pre-boot cycles consist of four commands:
[0418] 1. Capture: After a 10 s stabilization period, the variable solution was injected into the second flow cell at a flow rate of 10 μl / min for 30 s.
[0419] 2. Sample: Single cycle kinetics consisting of four different concentrations (0.5 nM, 5 nM, 50 nM, 500 nM) was injected into flow cells three and four at a flow rate of 30 μl / min. The association and dissociation times were set to 180 sec and 1200 sec.
[0420] 3. Regeneration: 100 mM glycine-HCl, pH 1.5, was injected into both flow cells at a flow rate of 30 μl / min for 40 seconds.
[0421] 4. Regeneration: Same settings as the previous command plus a 10 second stabilization period.
[0422] A sample set consisting of four different antigens 1) monomeric huAG1-His-tag, 2) monomeric huAG2-His-tag, 3) a mixture of monomeric huAG1-His-tag and monomeric huAG2-His-Tag, and 4) huAG1-huAG2-bispecific-Fc fusion-His-tag was used in the capture step at different concentrations of 10 nM, 100 nM, and 1000 nM to generate the sensor surface.
[0423] Then, a concentration series of bispecific anti-AG1 / AG2 antibodies was injected and allowed to bind to individual antigens, antigen mixtures, and antigen fusions in subsequent measurement cycles, always accompanied by a corresponding blank cycle for subsequent reference.
[0424] The resulting data were then processed using the BIAcore T200 Evaluation Software. Where possible, a 1:1 Langmuir fit was created.
[0425] Example 3
[0426] Quality assessment of samples relative to reference standards
[0427] The method according to the invention is based on an SPR assay using a BIAcore instrument (GE Healthcare) as exemplified in this example. Any other instrument may also be used.
[0428] In this example, a bivalent bispecific antibody with a domain swap format having mutations P329G and L234A / L235A in the Fc region (denoted herein as LALA PG; according to Kabat numbering) was used. Likewise, any other mutation in the Fc region can be used as long as there is a capture agent that specifically binds to it.
[0429] In the first step, antibodies targeting L234A / L235A mutations or P329G mutations in the Fc region were fixed to a CM5 sensor chip using an amine coupling chemistry provided by GE Healthcare. The flow cell was activated using a 1:1 mixture of 0.4M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 0.1M N-hydroxysuccinimide (NHS) at a flow rate of 5μl / min. Anti-LALA antibody or anti-PG antibody was injected into sodium acetate at pH 5.0 for 1200 seconds at a concentration of 50μg / ml, resulting in a surface density of approximately 18000RU. At least 16000RU ("response binding") should be fixed to ensure that antibody capture is not limited by immobilization. The reference control flow cell was treated in the same manner as described above. Finally, both surfaces were blocked by injection of 1M ethanolamine / HCl pH 8.5. HBS-EP+ (10 mM HEPES, 150 mM NaCl pH 7.4, GE Healthcare) was used as fixation buffer.
[0430] Second, a domain-swapped version of the bivalent bispecific antibody containing the LALA PG mutation in the Fc region was diluted in HBS-EP+ (GE Healthcare) and injected at a flow rate of 5 μl / min for 60 sec.
[0431] Third, the Antigen 1-Antigen 2 Fc fusion according to the invention was injected at a concentration of 15 μg / ml for 60 seconds. The dissociation time (washing with running buffer) was 600 seconds at a flow rate of 30 μl / min. All interactions were performed at 25°C.
[0432] Fourth, after each binding cycle, a regeneration solution of 10 mM NaOH was injected twice for 30 s at a flow rate of 30 μl / min to remove any non-covalently bound protein, followed by a 40 s stabilization period to stabilize the baseline.
[0433] Signals are detected at a rate of one signal per second. The binding response (resonance unit, RU) of antigen 1-antigen 2 Fc fusions is related to the amount of bivalent bispecific antibodies, and is mapped according to the sample concentration range used. The linear graph obtained is analyzed by appropriate computer software (such as XLfit4, IDBS software), and the software fits 2 parameter lines, so the y-axis intercept can be determined as a biological binding activity (=efficacy) reading. After parallel line conversion, the relative efficacy (=reportable efficacy) of the sample compared to the antibody reference standard can be reported.
[0434] Antigen 1 and Antigen 2 bind simultaneously to the captured bivalent bispecific antibody. The target binding response is used as the final assay readout.
[0435] The above method is intended to meet the potency release assay criteria of USP 1032, as disclosed by Gassner et al. (Gassner, C., et al. J. Pharm. Biomed. Anal. 102 (2015) 144-149). However, if it is not necessary to meet the USP 1032 criteria, it is sufficient to measure a single concentration and plot it against a calibration curve of a reference standard.
[0436] Example 4
[0437] Quality assessment of samples relative to reference standards
[0438] The method according to the invention is based on an SPR assay using a BIAcore instrument (GE Healthcare) as exemplified in this example. Any other instrument may also be used.
[0439] In this example, an Antigen 1-Antigen 2 Fc fusion with mutations P329G and L234A / L235A in the Fc region (denoted herein as LALA PG; according to Kabat numbering) was used. Likewise, any other mutation in the Fc region can be used as long as there is a capture agent that specifically binds to it.
[0440] In the first step, the antibody with L234A / L235A mutation or P329G mutation in the Fc region of the targeting antigen 1-antigen 2 Fc fusion was fixed to a CM5 sensor chip using the amine coupling chemistry provided by GE Healthcare. The flow cell was activated with a flow rate of 5 μl / min using a 1:1 mixture of 0.4M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 0.1M N-hydroxysuccinimide (NHS). Anti-LALA antibody or anti-PG antibody was injected into sodium acetate at pH 5.0 for 1200 seconds at a concentration of 50 μg / ml, resulting in a surface density of about 18000RU. At least 16000RU ("response binding") should be fixed to ensure that antibody capture is not limited by immobilization. The reference control flow cell was treated in the same manner as described above. Finally, the two surfaces were blocked by injecting 1M ethanolamine / HCl pH 8.5. HBS-EP+ (10 mM HEPES, 150 mM NaCl pH 7.4, GE Healthcare) was used as fixation buffer.
[0441] Next, the Antigen 1 - Antigen 2 Fc fusion according to the present invention was injected at a flow rate of 5 μl / min for 60 seconds.
[0442] Third, the bivalent bispecific antibodies in domain exchange format were diluted in HBS-EP+ (GE Healthcare) and injected at different concentrations for 60 seconds at a concentration of 15 μg / ml. The dissociation time (washing with running buffer) was 600 seconds at a flow rate of 30 μl / min. All interactions were performed at 25°C.
[0443] Fourth, after each binding cycle, a regeneration solution of 10 mM NaOH was injected twice for 30 s at a flow rate of 30 μl / min to remove any non-covalently bound protein, followed by a 40 s stabilization period to stabilize the baseline.
[0444] Signal is detected at a rate of one signal per second. The binding response (resonance unit, RU) of the bivalent bispecific antibody is related to the amount of antigen 1-antigen 2 Fc fusion, and is mapped according to the sample concentration range used. The linear graph obtained is analyzed by suitable computer software (such as XLfit4, IDBS software), and the software fits 2 parameter lines, so the y-axis intercept can be determined as biological binding activity (=effectiveness) reading. After the parallel line conversion, the relative effectiveness (=reportable effectiveness) of the sample compared with the antibody reference standard can be reported.
[0445] Captured Antigen 1 and Antigen 2 are simultaneously bound to the bivalent bispecific antibody. The target binding response is used as the final assay readout.
[0446] The above method is intended to meet the potency release assay criteria of USP 1032, as disclosed by Gassner et al. (Gassner, C., et al. J. Pharm. Biomed. Anal. 102 (2015) 144-149). However, if it is not necessary to meet the USP 1032 criteria, it is sufficient to measure a single concentration and plot it against a calibration curve of a reference standard.
Claims
1. A method for determining the affinity-based binding strength of an at least bivalent bispecific antibody to its first antigen and a second antigen, the method comprising - determining the avidity-based binding strength of the bivalent, bispecific antibody according to a surface plasmon resonance signal obtained by a) capturing the first antigen-second antigen fusion polypeptide on a surface plasmon resonance chip and Determine the first surface plasmon resonance response, b) applying to the surface plasmon resonance chip of step a) a material comprising at least a bispecific binding agent to form a captured first antigen-second antigen fusion polypeptide-bispecific binder complex and determine the second surface plasmon resonance response, c) calculating the at least two surface plasmon resonance responses from a difference between the first and second surface plasmon resonance responses the affinity-based binding strength of the specific binder for the first and second antigens, wherein at one end comprises the first antigen and at a second, different end comprises the said first antigen-second antigen fusion polypeptide is conjugated to a second antigen, wherein the at least bivalent bispecific antibody comprises a first binding site that specifically binds to a first antigen and a second binding site that specifically binds to a different second antigen, wherein the first antigen-second antigen fusion polypeptide is a heterodimeric polypeptide comprising a first polypeptide and a second polypeptide, wherein the first polypeptide is a fusion polypeptide of the first antigen and a first antibody heavy chain Fc region polypeptide comprising a first set of heterodimerization mutations, and the second polypeptide is a fusion polypeptide of the second antigen and a second antibody heavy chain Fc region polypeptide comprising a second set of heterodimerization mutations, and the second set of heterodimerization mutations are complementary to the first set of heterodimerization mutations, wherein the first antigen and the second antigen are at the N-terminus of the first antibody heavy chain Fc region polypeptide or the second antibody heavy chain Fc region polypeptide, wherein each first antigen-second antigen fusion polypeptide comprising the first antigen at one end and the second antigen at a different second end is conjugated to a surface plasmon resonance chip, The first antigen is different from the second antigen.
2. The method according to claim 1, comprising the steps of: a) capturing the first antigen-second antigen fusion polypeptide on a surface plasmon resonance chip, b) applying a first solution comprising a first concentration of the bivalent bispecific antibody to the surface plasmon resonance chip of step a) to form a captured first antigen-second antigen fusion polypeptide-bivalent bispecific antibody complex and determining a first surface plasmon resonance response, c) dissociating the captured first antigen-second antigen fusion polypeptide-bivalent bispecific antibody complex, and thereby regenerating the surface plasmon resonance chip, d) repeating at least steps b) and c) with a second solution comprising said bivalent, bispecific antibody at a second concentration and determining a second surface plasmon resonance response, wherein all concentrations are different, e) determining the avidity-based binding strength of said at least bivalent bispecific antibody to said first antigen and said second antigen according to said surface plasmon resonance response as determined in the previous step.
3. The method of claim 1 or 2, wherein the first antigen is at least a fragment of an epitope of the first antigen that comprises the first binding site of the bivalent bispecific antibody, and the second antigen is at least a fragment of an epitope of the second antigen that comprises the second binding site of the bivalent bispecific antibody. The method according to claim 1 , wherein the first antigen-second antigen fusion polypeptide comprises a tag for immobilization to a surface plasmon resonance chip. The method according to claim 3 , wherein the first antigen-second antigen fusion polypeptide comprises a tag for immobilization to a surface plasmon resonance chip. The method according to claim 4 , wherein the tag is at the C-terminus of the corresponding antibody heavy chain Fc region polypeptide. The method according to claim 5 , wherein the tag is at the C-terminus of the corresponding antibody heavy chain Fc region polypeptide. The method of claim 4 , wherein the antibody heavy chain Fc region is of human IgG1 isotype.
9. The method of claim 5, wherein the antibody heavy chain Fc region is of human IgG1 isotype.
10. The method of claim 7, wherein the antibody heavy chain Fc region is of human IgG1 isotype.
11. The method of claim 8 or 10, wherein the first group of heterodimerization mutations and the second group of heterodimerization mutations are T366W and T366S / L368A / Y407V, respectively, or T366S / L368A / Y407V and T366W, respectively.
12. The method of claim 9, wherein the first set of heterodimerization mutations and the second set of heterodimerization mutations are T366W and T366S / L368A / Y407V, or T366S / L368A / Y407V and T366W, respectively.
13. Use of a heterodimeric first antigen-second antigen fusion polypeptide for determining the affinity-based binding strength of a bispecific antibody to the first antigen and the second antigen in a surface plasmon resonance method, wherein the bispecific antibody comprises a first binding site that specifically binds to the first antigen and a second binding site that specifically binds to the second antigen, The heterodimeric first antigen-second antigen fusion polypeptide comprises i) a first polypeptide, and ii) a second polypeptide, in - the first polypeptide and the second polypeptide are the first antigen and the second antigen of a bispecific antibody, the bispecific antibody comprising a first binding site that specifically binds to the first polypeptide and a second binding site that specifically binds to the second polypeptide, - the first polypeptide is fused to the N-terminus of the first antibody heavy chain Fc region polypeptide of the IgG1 subtype, - the second polypeptide is fused to the N-terminus of the heavy chain Fc region polypeptide of the second antibody of the IgG1 subtype, - the first antibody heavy chain Fc region polypeptide and the second antibody heavy chain Fc region polypeptide form a disulfide-bonded heterodimer, - one or both of the antibody heavy chain Fc region polypeptides comprises a tag at its C-terminus for fixation to a surface plasmon resonance chip, - the first antibody heavy chain Fc region polypeptide and the second antibody heavy chain Fc region polypeptide comprise mutations T366W and T366S / L368A / Y407V, respectively, - each heterodimeric first antigen-second antigen fusion polypeptide comprising the first antigen at one end and the second antigen at a different second end is conjugated to the surface plasmon resonance chip, respectively, and - said first antigen is different from said second antigen.
14. A method for purifying a bispecific antibody having affinity-based binding to a first antigen and a second antigen from product-related and / or process-related impurities, the bispecific antibody comprising a first binding site that specifically binds to the first antigen and a second binding site that specifically binds to the second antigen, the method comprising the steps of: a) applying a solution comprising the bispecific antibody having avidity-based binding to a first antigen and a second antigen and process-related and / or product-related impurities to an affinity chromatography column comprising a heterodimeric first antigen-second antigen fusion polypeptide as a chromatographic ligand, b) optionally washing the affinity chromatography column, wherein the bispecific antibody having avidity-based binding to the first antigen and the second antigen remains bound to the affinity chromatography column, and c) recovering the bispecific antibody having affinity-based binding to a first antigen and a second antigen from the affinity chromatography column, and thereby purifying the bispecific antibody from product-related and / or process-related impurities; wherein the heterodimeric first antigen-second antigen fusion polypeptide comprises i) a first polypeptide, and ii) a second polypeptide, in - the first polypeptide and the second polypeptide are the first antigen and the second antigen of a bispecific antibody, the bispecific antibody comprising a first binding site that specifically binds to the first polypeptide and a second binding site that specifically binds to the second polypeptide, - the first polypeptide is fused to the N-terminus of the first antibody heavy chain Fc region polypeptide of the IgG1 subtype, - the second polypeptide is fused to the N-terminus of the heavy chain Fc region polypeptide of the second antibody of the IgG1 subtype, - the first antibody heavy chain Fc region polypeptide and the second antibody heavy chain Fc region polypeptide form a disulfide-bonded heterodimer, - one or both of the antibody heavy chain Fc region polypeptides comprises a tag at its C-terminus for fixation to a surface plasmon resonance chip, - the first antibody heavy chain Fc region polypeptide and the second antibody heavy chain Fc region polypeptide comprise mutations T366W and T366S / L368A / Y407V, respectively, and - said first antigen is different from said second antigen.
15. A method for assessing the quality of a sample comprising at least a bivalent bispecific antibody, the method comprising the following steps: - applying solutions containing a first antigen-second antigen fusion polypeptide comprising the first antigen of the bivalent bispecific antibody at one end and the second antigen of the bivalent bispecific antibody at a different second end to a surface plasmon resonance chip on which the bivalent bispecific antibody has been immobilized at different concentrations, respectively, and then monitoring a surface plasmon resonance signal, and - comparing the determined reading to a reference sample and thereby determining the quality of said sample comprising said at least bivalent bispecific antibody, wherein the at least bivalent bispecific antibody comprises a first binding site that specifically binds to a first antigen and a second binding site that specifically binds to a different second antigen, wherein the first antigen-second antigen fusion polypeptide is a heterodimeric polypeptide comprising a first polypeptide and a second polypeptide, wherein the first polypeptide is a fusion polypeptide of the first antigen and a first antibody heavy chain Fc region polypeptide comprising a first set of heterodimerization mutations, and the second polypeptide is a fusion polypeptide of the second antigen and a second antibody heavy chain Fc region polypeptide comprising a second set of heterodimerization mutations, and the second set of heterodimerization mutations are complementary to the first set of heterodimerization mutations, wherein the first antigen and the second antigen are at the N-terminus of the first antibody heavy chain Fc region polypeptide or the second antibody heavy chain Fc region polypeptide, wherein each first antigen-second antigen fusion polypeptide comprising the first antigen at one end and the second antigen at a different second end is conjugated to a surface plasmon resonance chip, The first antigen is different from the second antigen.
16. The method according to claim 15, wherein the method comprises the following steps - applying solutions containing a first antigen-second antigen fusion polypeptide comprising the first antigen of the bivalent bispecific antibody at one end and the second antigen of the bivalent bispecific antibody at a different second end to a surface plasmon resonance chip on which the bivalent bispecific antibody has been immobilized at different concentrations, respectively, and then monitoring a surface plasmon resonance signal, - Plot the binding response against the corresponding sample concentration, - fit the data points of the obtained plot using a 2-parameter line fit and determine the y-intercept as the readout, - comparing the determined readings with the readings of reference samples analyzed and processed in the same way by means of a parallel line transformation, thereby determining the quality of said sample comprising said at least bivalent bispecific antibody, wherein the at least bivalent bispecific antibody comprises a first binding site that specifically binds to a first antigen and a second binding site that specifically binds to a different second antigen, wherein the first antigen-second antigen fusion polypeptide is a heterodimeric polypeptide comprising a first polypeptide and a second polypeptide, wherein the first polypeptide is a fusion polypeptide of the first antigen and a first antibody heavy chain Fc region polypeptide comprising a first set of heterodimerization mutations, and the second polypeptide is a fusion polypeptide of the second antigen and a second antibody heavy chain Fc region polypeptide comprising a second set of heterodimerization mutations, and the second set of heterodimerization mutations are complementary to the first set of heterodimerization mutations, wherein the first antigen and the second antigen are at the N-terminus of the first antibody heavy chain Fc region polypeptide or the second antibody heavy chain Fc region polypeptide, wherein each first antigen-second antigen fusion polypeptide comprising the first antigen at one end and the second antigen at a different second end is conjugated to a surface plasmon resonance chip, The first antigen is different from the second antigen.
17. A method for selecting a cell line producing an at least bivalent bispecific antibody, the method comprising the steps of: - providing a corresponding supernatant isolated from a plurality of recombinant mammalian cell lines expressing the at least bivalent bispecific antibody, - for each cell line, applying a solution comprising a first antigen-second antigen fusion polypeptide comprising the first antigen of the bivalent bispecific antibody at one end and the second antigen of the bivalent bispecific antibody at a different second end, the bivalent bispecific antibody from the culture supernatant of the cell line being immobilized on the surface plasmon resonance chip, respectively, at different concentrations, and then monitoring the surface plasmon resonance signal; or For each cell line, a solution containing the bivalent bispecific antibody from the culture supernatant of the cell line is applied at different concentrations to a surface plasmon resonance chip on which a first antigen-second antigen fusion polypeptide has been immobilized, the first antigen-second antigen fusion polypeptide comprising the first antigen of the bivalent bispecific antibody at one end and the second antigen of the bivalent bispecific antibody at a different second end, and then a surface plasmon resonance signal is monitored, - comparing the determined readouts to each other and thereby determining the relative quality of said at least bivalent bispecific antibody produced by each cell line, as well as - selecting at least one cell line based on the relative quality of the at least bivalent bispecific antibody produced, wherein the at least bivalent bispecific antibody comprises a first binding site that specifically binds to a first antigen and a second binding site that specifically binds to a different second antigen, wherein the first antigen-second antigen fusion polypeptide is a heterodimeric polypeptide comprising a first polypeptide and a second polypeptide, wherein the first polypeptide is a fusion polypeptide of the first antigen and a first antibody heavy chain Fc region polypeptide comprising a first set of heterodimerization mutations, and the second polypeptide is a fusion polypeptide of the second antigen and a second antibody heavy chain Fc region polypeptide comprising a second set of heterodimerization mutations, and the second set of heterodimerization mutations are complementary to the first set of heterodimerization mutations, wherein the first antigen and the second antigen are at the N-terminus of the first antibody heavy chain Fc region polypeptide or the second antibody heavy chain Fc region polypeptide, wherein each first antigen-second antigen fusion polypeptide comprising the first antigen at one end and the second antigen at a different second end is conjugated to a surface plasmon resonance chip, The first antigen is different from the second antigen.
18. The method according to claim 17, wherein the method comprises the following steps - providing a corresponding supernatant isolated from a plurality of recombinant mammalian cell lines expressing the at least bivalent bispecific antibody, - for each cell line, applying a solution comprising a first antigen-second antigen fusion polypeptide comprising the first antigen of the bivalent bispecific antibody at one end and the second antigen of the bivalent bispecific antibody at a different second end, the bivalent bispecific antibody from the culture supernatant of the cell line being immobilized on the surface plasmon resonance chip, respectively, at different concentrations, and then monitoring the surface plasmon resonance signal; or For each cell line, a solution containing the bivalent bispecific antibody from the culture supernatant of the cell line is applied at different concentrations to a surface plasmon resonance chip on which a first antigen-second antigen fusion polypeptide has been immobilized, the first antigen-second antigen fusion polypeptide comprising the first antigen of the bivalent bispecific antibody at one end and the second antigen of the bivalent bispecific antibody at a different second end, and then a surface plasmon resonance signal is monitored, - Plot the binding response against the corresponding sample concentration, - fitting the data points of the obtained graph using a 2-parameter line fit and determining the y-intercept as readout, thereby determining the relative quality of said at least bivalent bispecific antibody produced by each cell line, as well as - selecting at least one cell line based on the relative quality of the at least bivalent bispecific antibody produced, wherein the at least bivalent bispecific antibody comprises a first binding site that specifically binds to a first antigen and a second binding site that specifically binds to a different second antigen.
